{
  "dataset": "ist3",
  "total_mechanisms_analyzed": 13,
  "total_abstracts_retrieved": 199,
  "overall_support_count": 6,
  "overall_conflict_count": 0,
  "overall_neutral_count": 193,
  "mechanism_results": [
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Higher NIHSS suggests larger ischemic cores and penumbra, reducing alteplase effectiveness due to its rapid occlusion and limited perfusion capacity within the therapeutic window.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"effectiveness\" OR \"therapeutic\" OR \"alteplase\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad review description about stroke pathophysiology, therapeutic targets, and research trends. It does not mention NIHSS, infarct core size, penumbra extent, alteplase effectiveness, or how stroke severity relates to thrombolysis outcomes, so it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "The abstract states that ischemic stroke is common, that therapy focuses on restoring blood flow and treating neurological damage, and that there have been advances in understanding pathophysiology and therapeutic targets. No quantitative or qualitative data are provided regarding NIHSS scores, ischemic core/penumbra size, or alteplase treatment response.",
          "pmid": "33076218",
          "title": "Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that treatment effects of endovascular thrombectomy vs standard care do not vary by baseline NIHSS (stroke severity) after adjustment, but it does not analyze how higher NIHSS relates to alteplase effectiveness, ischemic core/penumbra size, or perfusion limitations. The proposed mechanism specifically concerns alteplase efficacy decreasing with higher NIHSS due to larger cores/penumbra, which is not directly evaluated.",
          "key_findings": "Baseline NIHSS is included as an adjustment variable and in subgroup analyses for thrombectomy benefit, and no heterogeneity of treatment effect is found across prespecified subgroups, but the abstract provides no data on how NIHSS modifies the effect of intravenous alteplase or relates mechanistically to ischemic core/penumbra size or alteplase perfusion/occlusion dynamics.",
          "pmid": "26898852",
          "title": "Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes and safety between tenecteplase and alteplase but does not analyze outcomes stratified by baseline NIHSS, ischemic core size, or penumbra, nor does it examine how higher NIHSS might reduce alteplase effectiveness due to core/penumbra dynamics. No data are presented that link NIHSS severity to differential efficacy of alteplase within the therapeutic window, so the proposed mechanism is neither supported nor contradicted.",
          "key_findings": "In a randomized trial of 1600 acute ischemic stroke patients treated within 4.5 hours, tenecteplase 0.25 mg/kg was non-inferior to alteplase 0.9 mg/kg regarding functional independence (mRS 0\u20131 at 90\u2013120 days: 36.9% vs 34.8%; risk difference 2.1%, 95% CI \u22122.6 to 6.9). Symptomatic intracerebral hemorrhage and 90-day mortality rates were similar between groups. The abstract does not report outcomes by NIHSS, core size, or penumbra, nor mechanistic analyses of alteplase effectiveness relative to stroke severity.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thrombolytic agents, adjunct therapies, and systems of care (mobile stroke units, neuroimaging to identify salvageable penumbra) but does not address how NIHSS relates to ischemic core/penumbra size or to alteplase effectiveness. It provides no data or claims about differential alteplase efficacy according to stroke severity scores or perfusion limits within the therapeutic window.",
          "key_findings": "Alteplase is the only approved thrombolytic; tenecteplase is a potential alternative, particularly in large vessel occlusion. Research focuses on adjunct therapies, preventing reocclusion, intra-arterial thrombolysis after thrombectomy, and using mobile stroke units and advanced neuroimaging to increase thrombolysis use by shortening onset-to-treatment times and identifying salvageable penumbra. No mention is made of NIHSS, ischemic core size, or alteplase effectiveness as a function of stroke severity.",
          "pmid": "36907201",
          "title": "Thrombolysis for acute ischaemic stroke: current status and future perspectives.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates endovascular thrombectomy versus standard care in late-presenting stroke patients selected by a clinical\u2013imaging mismatch. It does not examine alteplase effectiveness, the relationship between NIHSS and ischemic core/penumbra size, or how higher NIHSS might reduce IV thrombolysis efficacy within the therapeutic window. Thus, it neither supports nor contradicts the proposed alteplase-related mechanism.",
          "key_findings": "In patients 6\u201324 hours after stroke onset with a mismatch between clinical deficit and infarct volume and large-artery occlusion, thrombectomy plus standard care significantly improved 90-day disability and functional independence compared with standard care alone, without significant increases in symptomatic intracranial hemorrhage or mortality.",
          "pmid": "29129157",
          "title": "Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of intravenous tirofiban given before endovascular thrombectomy on functional outcomes and hemorrhagic complications in large vessel occlusion stroke. It does not examine alteplase responsiveness, ischemic core/penumbra size, NIHSS severity, or how these factors influence thrombolytic effectiveness, so it neither supports nor contradicts the proposed mechanism about higher NIHSS reflecting larger cores/penumbra that reduce alteplase effectiveness.",
          "key_findings": "In a randomized, double-blind, placebo-controlled trial of 948 patients with proximal large vessel occlusion undergoing endovascular thrombectomy, pre-thrombectomy tirofiban did not improve 90-day modified Rankin Scale scores compared with placebo (adjusted common OR 1.08, 95% CI 0.86-1.36). Symptomatic intracranial hemorrhage was 9.7% with tirofiban vs 6.4% with placebo. The study conclusion is that tirofiban before thrombectomy does not improve functional outcomes, but it does not analyze alteplase efficacy, NIHSS, or ischemic core/penumbra characteristics.",
          "pmid": "35943471",
          "title": "Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism concerns how higher NIHSS (as a proxy for larger core/penumbra) affects alteplase effectiveness via perfusion and rapid occlusion. This trial focuses on endovascular therapy vs. medical care in patients with large infarcts defined by ASPECTS, not by NIHSS strata, and provides no direct comparison of alteplase effectiveness across different NIHSS or infarct sizes. Alteplase was used similarly in both arms and its specific efficacy in relation to NIHSS or core size is not analyzed.",
          "key_findings": "Patients with large infarcts (ASPECTS 3\u20135) had better 90\u2011day functional outcomes and more intracranial hemorrhages with endovascular therapy plus medical care vs. medical care alone. About 27% in each group received alteplase, but no results are stratified by NIHSS severity or directly evaluate how infarct size or NIHSS modify alteplase effectiveness.",
          "pmid": "35138767",
          "title": "Endovascular Therapy for Acute Stroke with a Large Ischemic Region.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study compares tenecteplase versus alteplase and uses NIHSS only as a minimisation variable in randomisation. It reports imaging-based penumbra salvage and clinical/radiological outcomes between drugs but does not analyze how higher NIHSS relates to ischemic core/penumbra size or to alteplase effectiveness within the treatment window. Thus, it neither tests nor comments on the proposed mechanism that higher NIHSS implies larger cores/penumbra and reduced alteplase efficacy.",
          "key_findings": "Adults with acute supratentorial ischemic stroke within 4.5 hours were randomized to tenecteplase or alteplase, with age and NIHSS used in the randomisation algorithm. Baseline CT, CT perfusion, and CT angiography were performed, and the primary endpoint was percentage of penumbra salvaged based on perfusion imaging and follow-up infarct volume. There were no significant differences between tenecteplase and alteplase in percentage penumbra salvaged, symptomatic ICH, total ICH, serious adverse events, or neurological and radiological outcomes. No analyses relating NIHSS severity to core/penumbra volumes or treatment effect of alteplase were reported.",
          "pmid": "25726502",
          "title": "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses watershed strokes, their border-zone location, hypoperfusion and embolic mechanisms, and imaging/diagnostic considerations, but it does not mention NIHSS scores, ischemic core/penumbra size, alteplase effectiveness, or any relationship between stroke severity and thrombolytic response. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Watershed strokes occur in border zones between major cerebral artery territories; mechanisms include cerebral hypoperfusion and arterial embolism from unstable atheroma; imaging aspects and clinical characteristics are highlighted to guide diagnosis and management, but treatment response to alteplase or links to stroke severity scales like NIHSS are not addressed.",
          "pmid": "37675172",
          "title": "Diagnosis and treatment of Watershed strokes: a narrative review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The mechanism concerns how higher NIHSS, reflecting larger ischemic core/penumbra, reduces alteplase effectiveness via perfusion/occlusion dynamics. This trial instead restricts enrollment to very low NIHSS (0\u20135) with minor, nondisabling deficits and compares alteplase vs aspirin, without stratifying outcomes by NIHSS within this narrow range or examining ischemic core/penumbra size or perfusion-related mechanisms. It only shows no overall benefit of alteplase in minor strokes, which does not directly test or contrast outcomes across higher vs lower NIHSS or link NIHSS to tissue-level mechanisms of alteplase effectiveness.",
          "key_findings": "Patients with acute ischemic stroke and minor nondisabling deficits (NIHSS 0\u20135) treated within 3 hours were randomized to alteplase or aspirin. Favorable functional outcome at 90 days was similar between groups (78.2% alteplase vs 81.5% aspirin; adjusted risk difference \u22121.1%; 95% CI \u22129.4% to 7.3%). Symptomatic intracranial hemorrhage occurred in 3.2% of alteplase patients and 0% of aspirin patients. The study does not report differential alteplase efficacy by higher vs lower NIHSS beyond this minor-stroke range, nor any measures of ischemic core or penumbra size.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the effect of virtual reality\u2013based rehabilitation plus conventional rehabilitation versus conventional rehabilitation alone on functional and neurological outcomes (including NIHSS) in subacute and chronic stroke. It does not analyze relationships between baseline NIHSS, ischemic core/penumbra size, alteplase effectiveness, or perfusion within the thrombolysis therapeutic window. No data on acute reperfusion therapy or imaging markers of core/penumbra are presented, so the proposed mechanism is neither supported nor contradicted.",
          "key_findings": "RFVE combined with conventional rehabilitation led to greater improvements than conventional rehabilitation alone in Fugl-Meyer upper extremity scores, FIM, NIHSS, ESAS, and kinematic measures; stroke etiology (ischemic vs hemorrhagic) did not significantly affect outcomes.",
          "pmid": "29453980",
          "title": "Virtual Reality for Upper Limb Rehabilitation in Subacute and Chronic Stroke: A Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sonothrombolysis and how ultrasound can enhance tPA-mediated thrombolysis, but it does not address NIHSS scores, ischemic core or penumbra size, or how stroke severity might modulate alteplase effectiveness within the therapeutic window. Therefore, it neither supports nor contradicts the proposed mechanism about higher NIHSS implying larger cores/penumbra and reduced alteplase effectiveness.",
          "key_findings": "Ultrasound combined with tPA can increase thrombolysis (up to 20% in static models and recanalization from 30% to 90% in flow models) and reduce infarct volume in embolic rat models; safety concerns include secondary hemorrhages in a phase II clinical study. No data are provided on NIHSS, core/penumbra size, or alteplase effectiveness stratified by stroke severity.",
          "pmid": "17290133",
          "title": "Sonothrombolysis: experimental evidence.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates intravenous glibenclamide for cerebral edema after large hemispheric infarction and reports NIHSS values only as a baseline characteristic. It does not analyze how higher NIHSS relates to ischemic core/penumbra size, alteplase effectiveness, or perfusion dynamics, nor does it assess treatment response stratified by NIHSS or thrombolysis status. Therefore, it neither supports nor contradicts the proposed mechanism about NIHSS reflecting larger cores/penumbra and reduced alteplase effectiveness.",
          "key_findings": "Patients had large hemispheric infarctions defined by low ASPECTS or large core volume; median NIHSS was 19 in both groups. The trial tested intravenous glibenclamide vs placebo, with no significant improvement in 90-day modified Rankin Scale or mortality. No data were presented on alteplase effectiveness, its interaction with NIHSS, or how stroke severity influenced reperfusion treatment response.",
          "pmid": "39577921",
          "title": "Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke inflammation, neuroprotective anti-inflammatory strategies, and their potential to extend the therapeutic window for tPA, but it does not address NIHSS scores, ischemic core size, penumbra extent, or how these factors influence alteplase effectiveness within the therapeutic window. Therefore it neither supports nor contradicts the proposed mechanism about higher NIHSS implying larger cores/penumbra and reduced alteplase efficacy.",
          "key_findings": "Stroke triggers a prolonged inflammatory reaction; anti-inflammatory treatments in animal models reduce infarct volume and improve outcomes even when started after 3 hours; such neuroprotective approaches might widen the therapeutic window for tPA and lessen its side effects; clinical anti-inflammatory trials in acute ischemic stroke have so far not improved outcomes.",
          "pmid": "16410192",
          "title": "Inflammation following stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses COVID-19\u2013associated coagulopathy, endothelial dysfunction, hypercoagulable state, and compromised stroke care, but does not mention NIHSS scores, ischemic core/penumbra size, alteplase effectiveness, or time-window\u2013related perfusion issues. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "SARS-CoV-2 infection is associated with increased D-dimer, fibrinogen, factor VIII, and von Willebrand factor, indicating coagulopathy and a hypercoagulable state that predisposes to cerebrovascular events; stroke care has been compromised due to healthcare system strain. No data are presented on stroke severity scales, core/penumbra size, or response to alteplase.",
          "pmid": "33225251",
          "title": "COVID-19 and stroke: A review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses system-based technologies and workflow improvements to expand and accelerate endovascular treatment for large vessel occlusion strokes. It does not address NIHSS scores, ischemic core size, penumbra, alteplase effectiveness, or how stroke severity might influence thrombolytic efficacy within the treatment window.",
          "key_findings": "Randomized trials show endovascular treatment superiority over medical management for anterior circulation ELVO; technological advances (mobile stroke units, telestroke, mobile endovascular teams, smartphone apps, modified screening tools, stroke registries) can shorten time to treatment and expand eligibility for endovascular therapy.",
          "pmid": "28366056",
          "title": "Expanding the treatment window for ischemic stroke through the application of novel system-based technology.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke urinary incontinence as a marker of stroke severity and its association with poorer outcomes, but it does not address NIHSS scores, ischemic core/penumbra size, alteplase treatment, or how stroke severity influences thrombolytic effectiveness within the therapeutic window.",
          "key_findings": "Urinary incontinence after stroke is common, correlates with greater stroke severity, and is associated with worse functional outcomes, higher institutionalization, and mortality; tailored continence management is associated with better stroke outcomes.",
          "pmid": "23834208",
          "title": "Post-stroke urinary incontinence.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on post-stroke depression, its predictors (including stroke severity), and treatments such as antidepressants, psychotherapy, and neuromodulation. It does not address NIHSS as a proxy for ischemic core/penumbra size, alteplase effectiveness, or any relationship between stroke severity/NIHSS and thrombolytic treatment outcomes or perfusion dynamics.",
          "key_findings": "Stroke severity is mentioned as a predictor of post-stroke depression, and SSRIs plus psychotherapy are described as effective treatments for PSD. There is no discussion of ischemic core size, penumbra, alteplase, reperfusion, or NIHSS-based differences in thrombolytic efficacy.",
          "pmid": "31236751",
          "title": "Treatment of Post-Stroke Depression.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses general management of ischemic stroke, including the time window and role of intravenous thrombolysis, but it does not address NIHSS scores, infarct core/penumbra size, or how stroke severity modifies alteplase effectiveness. Therefore it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Intravenous thrombolysis within 4.5 hours is described as the only proven therapy to improve functional outcome; endovascular recanalization and neuroprotective strategies have not yet demonstrated efficacy. The abstract outlines use and timing of antiplatelet agents and avoidance of anticoagulants early after stroke, plus supportive and secondary prevention measures. No data are provided on the relationship between initial stroke severity (e.g., NIHSS), ischemic core/penumbra size, and alteplase efficacy.",
          "pmid": "25007216",
          "title": "[Ischemic stroke--diagnosis and treatment].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of edaravone dexborneol versus placebo in patients undergoing endovascular thrombectomy and includes NIHSS- and ASPECTS-based subgroup definitions to characterize mismatch, but it does not analyze or report how higher NIHSS relates to ischemic core/penumbra size, nor how NIHSS modifies the effectiveness of alteplase specifically. The proposed mechanism concerns alteplase efficacy as a function of stroke severity (NIHSS), which is not addressed here.",
          "key_findings": "The trial enrolled patients with NIHSS 6\u201325 and ASPECTS 6\u201310 undergoing endovascular thrombectomy, randomizing them to edaravone dexborneol or placebo. Overall, edaravone dexborneol modestly improved 90-day functional independence versus placebo. A prespecified subgroup with imaging\u2013clinical mismatch (defined using thresholds of NIHSS and ASPECTS) appeared to benefit more. Alteplase use, its interaction with NIHSS, and direct relationships between NIHSS, ischemic core/penumbra size, and thrombolytic effectiveness were not evaluated.",
          "pmid": "41500725",
          "title": "Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Patients with severe occlusions indicated by high NIHSS scores may not respond well to alteplase due to insufficient recanalization.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"recanalization\" OR \"insufficient\" OR \"occlusions\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the success of endovascular thrombectomy added to intravenous thrombolytics, including for severe anterior circulation strokes, but it does not address whether patients with high NIHSS scores specifically fail to respond to alteplase due to insufficient recanalization. No direct comparison of alteplase efficacy by occlusion severity or NIHSS level is presented.",
          "key_findings": "Randomized controlled trials showed overwhelmingly positive results for EVT plus intravenous thrombolytics in anterior circulation stroke within 6 hours of onset, and even larger effects in the 6\u201324 hour window for patients with salvageable tissue. EVT is emphasized as enabling effective recanalization, but the abstract does not provide data on alteplase-alone recanalization rates in patients with severe occlusions or high NIHSS.",
          "pmid": "35172028",
          "title": "Endovascular thrombectomy for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke brain reorganization, general recovery factors, and mentions fibrinolytic treatment and recanalization in very broad terms, but it does not address NIHSS scores, severity of occlusions, alteplase-specific response, or insufficient recanalization in patients with high NIHSS. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Recovery after stroke is linked to brain plasticity and reorganization, with factors such as infarct volume and location, age, and risk factor control influencing prognosis. Fibrinolytic treatment within 3 hours is mentioned as important to prevent or minimize deficits, and improvement may be due partly to repair and recanalization, but no data are given on alteplase efficacy relative to stroke severity or NIHSS.",
          "pmid": "14681816",
          "title": "Brain reorganization after stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on seizure and poststroke epilepsy incidence and blood biomarkers after mechanical thrombectomy. While it reports NIHSS scores and recanalization rates, it does not analyze the relationship between high NIHSS, alteplase responsiveness, or recanalization failure specifically with respect to thrombolytic treatment. The study population underwent mechanical thrombectomy, not alteplase efficacy assessment, so it does not address whether patients with severe occlusions and high NIHSS respond poorly to alteplase due to insufficient recanalization.",
          "key_findings": "In 90 patients with acute anterior ischemic stroke treated with mechanical thrombectomy, median NIHSS on admission was 18 and recanalization was achieved in 90%. Incidence of acute symptomatic seizures and poststroke epilepsy was 4.4% each, with an estimated 2-year PSE risk of 5.3%. Blood markers of brain injury (NFL, tau, GFAP, S100B, NSE) tended to be above the cohort median in patients who developed PSE. No data are provided on alteplase response or comparative recanalization failure in high NIHSS patients treated with thrombolysis.",
          "pmid": "31526644",
          "title": "Acute symptomatic seizures and epilepsy after mechanical thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes the design of a trial evaluating ultrasound-enhanced thrombolysis with alteplase in MCA occlusions and mentions NIHSS as an outcome measure, but it does not analyze or report any relationship between baseline NIHSS severity, degree of occlusion, and the likelihood of recanalization or clinical response to alteplase alone. No data are given on alteplase nonresponse in patients with high NIHSS or severe occlusions.",
          "key_findings": "All enrolled patients have MCA occlusion on TCD and receive standard-dose IV tPA; they are randomized to additional continuous TCD monitoring vs placebo to test enhancement of thrombolysis. Outcomes include early complete recanalization (TIBI 4\u20135) and clinical recovery measured by NIHSS changes. However, the abstract provides no results and does not examine or stratify outcomes by initial NIHSS severity or occlusion severity, so it does not address whether patients with severe occlusions/high NIHSS respond poorly to alteplase due to insufficient recanalization.",
          "pmid": "15095554",
          "title": "CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on blood pressure variability after endovascular thrombectomy and its association with outcomes, adjusting for stroke severity and recanalization status. It does not analyze alteplase response, NIHSS-based occlusion severity effects on thrombolysis, or recanalization specifically with IV alteplase, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Higher systolic blood pressure variability within 24 hours after EVT is associated with increased 90-day mortality and disability, independent of mean blood pressure levels; no association was found with symptomatic intracranial hemorrhage.",
          "pmid": "37921233",
          "title": "Association between blood pressure variability and outcomes after endovascular thrombectomy for acute ischemic stroke: An individual patient data meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports recanalization and clinical recovery rates in patients with proximal occlusions treated with IV alteplase plus continuous TCD monitoring, but it does not stratify outcomes by NIHSS severity or explicitly analyze whether patients with higher NIHSS (severe occlusions) respond less well to alteplase due to insufficient recanalization. Therefore, it does not directly test or quantify the proposed relationship between high NIHSS and poor alteplase response via inadequate recanalization.",
          "key_findings": "In 55 stroke patients (median NIHSS 18) with proximal arterial occlusion treated with IV tPA within 3 hours and monitored by TCD, complete recanalization within 2 hours occurred in 36%. Dramatic recovery (NIHSS \u22643) was seen in 20% at 2 hours and 24% at 24 hours; \u22654-point NIHSS improvement occurred in 49% at 24 hours. Clinical improvement was associated with recanalization (phi r2=.5, P=.03). The study does not analyze outcomes by different baseline NIHSS strata or specifically address whether patients with the most severe occlusions (highest NIHSS) exhibit insufficient recanalization with alteplase.",
          "pmid": "15095555",
          "title": "Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ischemic stroke treatment, thrombolysis with rtPA in general, and potential roles of statins and PDE inhibitors via NO/cGMP pathways and collateral circulation. It does not address NIHSS scores, severity of occlusions, or differential alteplase responsiveness based on occlusion severity or recanalization rates, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "1) rtPA is described as the only approved drug for acute ischemic stroke to achieve early arterial recanalization and reperfusion, with efficacy that is time-dependent and associated with hemorrhagic risk. 2) Collateral blood supply and endothelial NO-dependent function are highlighted as important for rescuing ischemic penumbra. 3) Statins are reported to affect endothelial NO production and endothelial NO synthase, and PDE inhibitors increase cGMP and improve functional recovery after stroke in animal models. No data are given on recanalization success or alteplase response stratified by stroke severity or NIHSS.",
          "pmid": "17979792",
          "title": "Saving the ischemic penumbra: potential role for statins and phosphodiesterase inhibitors.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines baseline NIHSS as a predictor of functional outcome and alpha2-antiplasmin as a predictor of recanalization in rt-PA\u2013treated stroke patients. It does not analyze whether higher (or lower) NIHSS scores are associated with different recanalization rates or differential response to alteplase, so it neither supports nor contradicts the proposed mechanism about severe occlusions (high NIHSS) leading to insufficient recanalization.",
          "key_findings": "In 63 ischemic stroke patients treated with IV rt-PA and documented baseline occlusion, lower baseline alpha2-antiplasmin levels independently predicted recanalization (OR 0.95, 95% CI 0.91\u20130.99). Baseline NIHSS score independently predicted 3\u2011month functional outcome (OR 0.81, 95% CI 0.72\u20130.92), but was not reported as a predictor of recanalization. The study concludes that alpha2-antiplasmin, not NIHSS, predicts recanalization, and that these hemostatic markers were not related to long-term outcome.",
          "pmid": "16087899",
          "title": "Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study examines how increases in end-diastolic flow velocity predict recanalization and neurological improvement in patients with proximal intracranial occlusions treated with tPA, but it does not stratify outcomes by baseline NIHSS severity or analyze whether patients with higher NIHSS scores have poorer recanalization or response to alteplase. Thus, it does not directly address whether severe occlusions/high NIHSS are specifically associated with insufficient recanalization or poor alteplase response.",
          "key_findings": "Among 36 patients with proximal intracranial occlusions treated with systemic or intra-arterial tPA, 36% achieved complete recanalization. Those with complete recanalization had a greater increase in end-diastolic velocity (15 \u00b1 11 vs 6 \u00b1 10 cm/s; P=0.001), while peak systolic velocity changes were not significantly different. EDV increase correlated with 24-hour neurological improvement (Spearman r=0.337; P=0.044) and was higher in patients with favorable 3\u2011month functional outcome (13 \u00b1 13 vs 4 \u00b1 8 cm/s; P=0.021). After adjustment for confounders including baseline stroke severity, a 10 cm/s EDV increase was independently associated with a 3\u2011point NIHSS decline at 24 hours. The abstract does not specify how response to alteplase varies by initial NIHSS level.",
          "pmid": "20224054",
          "title": "End-diastolic velocity increase predicts recanalization and neurological improvement in patients with ischemic stroke with proximal arterial occlusions receiving reperfusion therapies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines ASL hyperperfusion, its association with recanalization-related factors and clinical outcomes, but does not analyze differential response to alteplase based on occlusion severity or NIHSS, nor does it address insufficient recanalization in high NIHSS patients specifically.",
          "key_findings": "ASL hyperperfusion after acute ischemic stroke correlates with symptom severity and 24h NIHSS, 90-day mRS, smaller infarct volume, larger penumbra salvage volume, and higher risk of hemorrhagic transformation; it is associated with thrombolysis and mechanical thrombectomy, but the abstract does not stratify thrombolysis effectiveness by occlusion severity or baseline NIHSS to test whether severe occlusions respond poorly to alteplase due to insufficient recanalization.",
          "pmid": "39846201",
          "title": "The prognostic impact of arterial spin labeling hyperperfusion in acute ischemic stroke: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effect of endovascular thrombectomy versus best medical therapy on cognitive outcomes in large-vessel occlusion stroke. It does not analyze alteplase responsiveness, NIHSS strata, recanalization success with alteplase, or differential outcomes by baseline stroke severity in the context of IV thrombolysis. Thus, it does not provide direct evidence for or against the proposed mechanism that patients with severe occlusions (high NIHSS) may not respond well to alteplase due to insufficient recanalization.",
          "key_findings": "Endovascular therapy (EVT) in the ESCAPE trial was associated with higher odds of favorable 90-day cognitive outcomes across multiple cognitive tests (MoCA, SNAP, BNT, Trails A, Trails B) and in global cognitive analyses, and both EVT and final infarct volume were significantly associated with cognitive outcome. The study population included patients with acute ischemic stroke due to intracranial ICA or M1 MCA occlusion, but the abstract does not report on alteplase effectiveness, recanalization rates with alteplase, or interactions with baseline NIHSS severity.",
          "pmid": "38739880",
          "title": "Effect of Endovascular Thrombectomy for Acute Ischemic Stroke on Cognitive Outcomes: A Secondary Analysis of the ESCAPE Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the role of collateral circulation in ischemic stroke, including its influence on recanalization, reperfusion, and outcomes, but it does not mention alteplase, NIHSS scores, or specifically whether patients with severe occlusions (high NIHSS) respond less well to alteplase due to insufficient recanalization. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Collateral perfusion influences arterial recanalization, reperfusion, hemorrhagic transformation, and neurological outcomes after stroke, and affects the time course of ischemic injury and stroke severity, but no data are presented regarding alteplase responsiveness or recanalization success stratified by NIHSS severity.",
          "pmid": "27224313",
          "title": "Collateral blood vessels in acute ischemic stroke: a physiological window to predict future outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses endovascular therapy versus IV/intra-arterial thrombolysis, recanalization rates, and clinical outcomes in general terms. It does not specifically analyze alteplase response as a function of occlusion severity or NIHSS score, nor does it present data on insufficient recanalization in high-NIHSS or severe-occlusion patients.",
          "key_findings": "Endovascular therapy is described as an alternative for patients ineligible for or who have failed IV thrombolysis; mechanical thrombectomy trials show higher recanalization but lower good-outcome rates compared with thrombolytic trials. Differences in clot location, burden, baseline stroke severity, time to treatment, and selection are mentioned, but no specific evidence is provided about alteplase effectiveness in high-NIHSS or severe-occlusion patients.",
          "pmid": "19386727",
          "title": "Endovascular approaches to acute stroke, part 2: a comprehensive review of studies and trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines safety and feasibility of adding ultrasound-activated perflutren microspheres to tPA and reports recanalization and NIHSS outcomes, but it does not analyze differential response to alteplase by baseline stroke severity or NIHSS-defined severity, nor does it address failure of recanalization specifically in patients with severe occlusions or high NIHSS.",
          "key_findings": "In this pilot RCT (n=15), adding ultrasound-activated perflutren-lipid microspheres to systemic tPA increased recanalization rates versus historical tPA+TCD controls (complete recanalization 50% vs 18%, P=0.028; sustained complete recanalization at 2 hours 42% vs 13%, P=0.003) without symptomatic intracranial hemorrhage. Asymptomatic ICH occurred in both groups. Microspheres reached MCA occlusions with higher velocities than residual RBC flow and improved residual flow velocity in most subjects. NIHSS 0\u20133 at 2 hours was 17% vs 8% (P=0.456). The study does not stratify by high NIHSS or explicitly examine insufficient recanalization in patients with severe occlusions.",
          "pmid": "18356546",
          "title": "A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates blood pressure management after successful endovascular thrombectomy in relation to infarct volume and functional outcomes. It does not examine alteplase efficacy, NIHSS scores, or recanalization failure in patients with severe occlusions, nor does it compare outcomes by thrombolytic response. Therefore it neither supports nor contradicts the proposed mechanism about poor alteplase response in high-NIHSS patients due to insufficient recanalization.",
          "key_findings": "In 300 patients with successful recanalization after EVT, conventional systolic blood pressure management (140\u2013180 mmHg) was associated with higher odds of functional independence at 3 months than intensive control (<140 mmHg) in patients with infarct volume \u226450 ml (AOR 2.06, 95% CI 1.12\u20133.86), while no significant difference was observed in those with infarct volume >50 ml. The interaction between infarct volume group and BP strategy was not significant, and as infarct volume increased, the impact of BP management on functional outcomes decreased.",
          "pmid": "40317165",
          "title": "Blood pressure management based on infarct volume after successful endovascular thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns reduced alteplase responsiveness in patients with severe occlusions as indicated by high NIHSS, due to insufficient recanalization. This abstract instead evaluates how collateral circulation (LMC score on PCT-SI) predicts outcome and early recovery after IV thrombolysis in MCA occlusion. NIHSS severity and recanalization are mentioned only descriptively and not analyzed as a function of occlusion severity or NIHSS strata, nor is there evidence specifically linking high NIHSS to reduced recanalization or poor alteplase response. Therefore it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "In 54 patients with MCA occlusion treated with IV thrombolysis (median NIHSS 10), higher leptomeningeal collateral scores on PCT-SI were associated with better 3\u2011month functional outcome, better early neurological recovery, smaller 24\u2011hour hypodensity volumes, and a trend toward higher 24\u2011hour recanalization rates. The study focuses on collateral status, not explicitly on the relationship between high NIHSS and insufficient recanalization after alteplase.",
          "pmid": "23278976",
          "title": "Collateral circulation on perfusion-computed tomography-source images predicts the response to stroke intravenous thrombolysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates combinations of neuroprotective agents (magnesium sulphate, melatonin, minocycline) in animal stroke models and how age and occlusion duration affect neuroprotection. It does not involve alteplase, thrombolysis, NIHSS scores, or recanalization success in relation to occlusion severity, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Combination neuroprotective therapy was not effective in the tested animal stroke models, even when testing in younger animals or with shorter occlusions. Age affected homeostasis and general health scores but not infarct volume or neurologic scores. No mention of alteplase, NIHSS, or recanalization outcomes.",
          "pmid": "20978519",
          "title": "Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract analyzes how individual NIHSS components change with early MCA recanalization after alteplase and how well they diagnose recanalization status. It does not evaluate differential alteplase efficacy or recanalization rates as a function of initial stroke severity (high vs low NIHSS) nor does it address insufficient recanalization specifically in patients with severe occlusions.",
          "key_findings": "All patients received standard-dose IV tPA within 3 hours; 27% achieved complete MCA recanalization at 120 minutes. All NIHSS components attributable to MCA occlusion contributed to NIHSS improvement after recanalization, clustering into left/right brain function groups. Gaze deviation and total NIHSS score were relatively good indicators of recanalization. The study does not stratify outcomes or recanalization success by baseline NIHSS severity or address non-response to alteplase in high NIHSS patients.",
          "pmid": "20133918",
          "title": "Pattern of response of National Institutes of Health Stroke Scale components to early recanalization in the CLOTBUST trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how early NIHSS trajectories predict 90-day functional outcomes in an endovascular thrombectomy trial (ESCAPE). It does not analyze response to alteplase specifically, nor does it relate high baseline NIHSS or severity to insufficient recanalization with alteplase. The focus is prognosis based on NIHSS change over time after treatment, not mechanistic differences in alteplase efficacy in severe occlusions.",
          "key_findings": "In the ESCAPE trial, 2-day NIHSS trajectories formed three groups (large improvement, minimal improvement, no improvement), and those with large early improvement had better 90-day modified Rankin Scale outcomes. The 2-day NIHSS trajectory subgroup was more accurate (84.5%) in predicting 90-day outcomes than baseline NIHSS, infarct volume, or 24-hour NIHSS change. The study concerns endovascular treatment and prognostic value of NIHSS trajectories rather than alteplase responsiveness in high-NIHSS, severe occlusion patients.",
          "pmid": "27924049",
          "title": "Early Trajectory of Stroke Severity Predicts Long-Term Functional Outcomes in Ischemic Stroke Subjects: Results From the ESCAPE Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The mechanism concerns poor alteplase response in patients with severe occlusions/high NIHSS due to insufficient recanalization. This study examines basilar artery occlusion treated with endovascular therapy, not specifically response to intravenous alteplase or its recanalization efficacy by NIHSS level. Although NIHSS predicts clinical outcome and recanalization predictors are analyzed, the abstract does not report alteplase-specific recanalization rates or differential efficacy in high NIHSS patients.",
          "key_findings": "In 148 basilar artery occlusion patients undergoing endovascular treatment, 59% received IV thrombolysis before EVT. Overall, TICI 2b\u20133 recanalization was achieved in 79%. Age, hypertension, NIHSS, collateral status, and MRI use predicted clinical outcome, with NIHSS, collateral status, and MRI remaining independent predictors. Better collateral status and use of a stent retriever independently predicted recanalization. Recanalization did not significantly predict clinical outcome. No alteplase-only recanalization outcomes or NIHSS-stratified IVT recanalization effects are reported.",
          "pmid": "25516154",
          "title": "Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "nihss",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Mismatch in ischemic damage versus therapeutic effect timeline lessens alteplase's functional independence recovery in severe strokes.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (NIHSS OR \"stroke severity\" OR \"neurological deficit\" OR \"infarct volume\") AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"independence\" OR \"therapeutic\" OR \"functional\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract compares tenecteplase with alteplase in terms of reperfusion and clinical outcomes but does not specifically analyze or discuss a mismatch between the time course of ischemic damage and alteplase\u2019s therapeutic effect as a mechanism for reduced functional independence in severe strokes. It reports outcome differences but does not mechanistically link them to temporal mismatch of damage versus drug effect for alteplase.",
          "key_findings": "In a phase 2B randomized trial of 75 acute ischemic stroke patients treated within 6 hours, tenecteplase (particularly 0.25 mg/kg) led to greater reperfusion and greater NIHSS improvement at 24 hours, and a higher rate of absence of serious disability at 90 days (72% vs 40% with alteplase; P=0.02). Safety profiles were similar. The study does not directly assess or attribute alteplase\u2019s lower functional independence rates to a mismatch between ischemic damage evolution and alteplase\u2019s therapeutic time course.",
          "pmid": "22435369",
          "title": "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares low-dose versus standard-dose alteplase (IV-tPA) in Asian populations and reports on functional outcomes and hemorrhage risk, but it does not analyze timelines of ischemic damage versus therapeutic effect, nor does it examine how any temporal mismatch affects functional independence recovery in severe strokes specifically. Therefore it neither supports nor contradicts the proposed time-mismatch mechanism.",
          "key_findings": "\u2022 Asian data on IV-tPA are limited; various low-, standard-, and variable-dose regimens are used.\n\u2022 Japanese case-controlled studies suggest low-dose IV-tPA (0.6 mg/kg) has comparable efficacy and safety to the standard 0.9 mg/kg dose.\n\u2022 Across non-Japanese Asian populations, functional outcomes with low-dose IV-tPA were similar to Japanese low-dose studies.\n\u2022 With standard-dose IV-tPA, considerably better functional outcomes were seen without higher symptomatic intracerebral hemorrhage rates.\n\u2022 No analysis is provided on timing of ischemic damage versus treatment effect or on how this temporal relationship influences functional independence recovery, particularly in severe strokes.",
          "pmid": "22111797",
          "title": "Current status of intravenous thrombolysis for acute ischemic stroke in Asia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aquaporin-4\u2019s role in stroke-related brain edema and potential therapeutic modulation, but does not mention alteplase, thrombolysis, timelines of ischemic damage vs. therapeutic effect, or functional independence outcomes. Therefore it neither supports nor refutes the proposed mechanism about alteplase\u2019s reduced functional independence recovery in severe stroke due to timeline mismatch.",
          "key_findings": "AQP4 has a biphasic role in cytotoxic vs. vasogenic edema in stroke, exacerbating acute cytotoxic edema while facilitating clearance in vasogenic edema; AQP4 is upregulated in infarcted regions, may serve as a biomarker, and is a target for emerging pharmacological strategies. No data are presented on alteplase, its therapeutic window, or functional recovery outcomes.",
          "pmid": "40943104",
          "title": "Aquaporin-4 in Stroke and Brain Edema-Friend or Foe?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses development of antioxidant/neuroprotective compounds for ischemic stroke and general issues of therapeutic windows and long-term neuroprotection, but it does not mention alteplase, thrombolysis-related timelines, or mismatches between ischemic damage evolution and alteplase\u2019s functional recovery effects. Therefore, it neither supports nor contradicts the specific proposed mechanism about alteplase in severe stroke.",
          "key_findings": "The paper is a review of pharmacological strategies with antioxidant and radical scavenger properties for acute ischemic stroke, including evaluation of antioxidant capacity, neuroprotection in neuronal cultures and in vivo models, neurological deficit scores, dose-response, therapeutic window, long-term neuroprotective effects, and in vivo antioxidant effects. It concludes that these compounds are promising for clinical trials but does not address alteplase or its timeline of therapeutic effect versus ischemic damage.",
          "pmid": "38136221",
          "title": "Development of Pharmacological Strategies with Therapeutic Potential in Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates erythropoietin and its analogues in animal stroke models, focusing on infarct size reduction, neurobehavioral improvement, dosing, and timing (\u22646 hours vs later). It does not examine alteplase, thrombolytic therapy, or the specific mismatch between ischemic damage evolution and alteplase\u2019s therapeutic time window, nor does it address functional independence outcomes in severe strokes. Therefore it neither supports nor contradicts the proposed alteplase-specific mechanistic timeline mismatch.",
          "key_findings": "In animal focal cerebral ischemia models, erythropoietin and its analogues reduced infarct size by about 32% and significantly improved neurobehavioral deficits when administered after onset of ischemia. Higher EPO doses were associated with smaller infarct volumes, and treatment started earlier than 6 hours was more effective than later initiation. Both hematopoietic and nonhematopoietic EPO analogues were efficacious. The authors suggest further studies on combining EPO with thrombolysis, but provide no data on alteplase or on ischemic damage vs therapeutic effect timeline for thrombolysis.",
          "pmid": "19542052",
          "title": "The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how baseline white matter hyperintensities predict long-term cognitive, functional, and mortality outcomes after ischemic stroke. It does not address alteplase, thrombolytic therapy, treatment timing, or any mismatch between ischemic damage evolution and therapeutic effect, so it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Moderate/severe baseline WMH are associated with higher long-term risk of dementia, cognitive and functional impairment, recurrent stroke, and mortality in ischemic stroke patients, with dose-response relationships and robustness to adjustment for confounders.",
          "pmid": "30770431",
          "title": "WMH and long-term outcomes in ischemic stroke: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cerebrospinal and interstitial fluid dynamics, edema, and secondary injury processes after ischemic stroke, but it does not mention alteplase, thrombolysis, therapeutic timelines, or functional independence outcomes. There is no direct evaluation of how a mismatch between ischemic damage progression and alteplase\u2019s therapeutic window affects recovery, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Ischemic stroke acutely alters CSF and ISF movement and exchange; early influx of CSF into perivascular spaces may contribute to cell swelling; impaired clearance over time exacerbates ionic and vasogenic edema, increases intracranial pressure, and worsens perfusion in the penumbra; mechanisms may include changes in arterial pulsatility, extracellular space structure, and aquaporin-4 localization; these CSF/ISF disturbances may contribute to post-stroke pathology and represent potential therapeutic targets. No data on alteplase or treatment-response timelines are provided.",
          "pmid": "40533800",
          "title": "Brain fluid physiology in ischaemic stroke; more than just oedema.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates carnosine as a neuroprotective agent in animal models of ischemic stroke, focusing on infarct volume reduction, dose-response, and treatment time window. It does not mention alteplase, thrombolysis, functional independence outcomes, or a mismatch between ischemic damage and therapeutic effect timelines, so it neither supports nor contradicts the proposed mechanism about alteplase\u2019s reduced functional recovery in severe strokes.",
          "key_findings": "Carnosine reduced infarct volume by about 29.4% in animal ischemic stroke models, showed a clear dose\u2013response, and lost efficacy when administered more than 6 hours after ischemia onset; studies were of moderate quality and conducted in healthy young male animals.",
          "pmid": "27401803",
          "title": "Systematic review and stratified meta-analysis of the efficacy of carnosine in animal models of ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates argatroban as an adjunct to antiplatelet therapy in mild\u2013moderate acute ischemic stroke and its impact on functional outcomes and safety, without examining alteplase, thrombolysis timelines, or mismatch between ischemic damage and therapeutic effect. It does not address mechanisms related to alteplase\u2019s reduced functional independence recovery in severe strokes or any temporal mismatch of its effects.",
          "key_findings": "Argatroban plus antiplatelets (especially with dual antiplatelet therapy) improved 90-day functional outcomes (higher mRS 0\u20132 and 0\u20131 rates), reduced early neurological deterioration, and improved NIHSS scores, without increasing intracranial hemorrhage, symptomatic ICH, stroke recurrence, or mortality, compared to antiplatelet therapy alone in acute ischemic stroke patients.",
          "pmid": "40392513",
          "title": "Exploring the Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke Patients: A Systematic Review and Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses neuroprotective effects and therapeutic time windows of BBB-targeted neurotrophin chimeric peptides in experimental stroke models, but it does not involve alteplase, thrombolysis, or the relationship between ischemic damage evolution and functional independence recovery in severe strokes. Therefore, it neither supports nor contradicts the proposed alteplase-specific mechanistic mismatch in damage-versus-therapy timelines.",
          "key_findings": "Chimeric neurotrophin peptides (e.g., BDNF, basic FGF) targeted across the BBB show neuroprotection in rat models of transient and permanent focal ischemia, with effective treatment windows of 1\u20132 hours after ischemia for BDNF and dose-dependent infarct reduction with basic FGF. Clinical neurotrophin trials have failed mainly due to poor BBB permeability, and future work focuses on improved delivery and combination therapies.",
          "pmid": "15717063",
          "title": "Neuroprotection in experimental stroke with targeted neurotrophins.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares low- vs standard-dose alteplase in acute ischemic stroke and reports improvements in neurological function and safety for both. It does not analyze timelines of ischemic damage versus therapeutic effect, nor does it assess functional independence recovery specifically in severe strokes or any mismatch between damage and therapeutic effect over time. Therefore it neither supports nor contradicts the proposed timing-mismatch mechanism.",
          "key_findings": "Randomized comparison of 0.6 mg/kg vs 0.9 mg/kg alteplase in acute ischemic stroke (n=86); both doses improved GCS and NIHSS scores; safety profile acceptable with non-persistent bleeding events; authors conclude that different alteplase doses can improve neurological function and living ability, but do not examine temporal mismatch of damage vs effect or focus on severe stroke subgroups.",
          "pmid": "31894036",
          "title": "Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates safety and some efficacy of combining reduced-dose rt-PA with eptifibatide versus standard-dose rt-PA within 3 hours of stroke onset. It does not analyze the temporal mismatch between ischemic damage evolution and alteplase\u2019s therapeutic window, nor does it examine functional independence specifically in relation to timing or severity-driven temporal mismatch. Any differences in efficacy reported are between drug regimens, not mechanistic timing of alteplase effect versus ischemic injury progression.",
          "key_findings": "The CLEAR trial randomized acute ischemic stroke patients within 3 hours of onset to low-dose rt-PA plus eptifibatide or standard-dose rt-PA alone. Symptomatic intracranial hemorrhage occurred in 1.4% of the combination group and 8.0% of the standard rt-PA group, suggesting acceptable safety of the combination. There was a trend toward increased clinical efficacy with standard-dose rt-PA compared with the combination group, but the trial was primarily a safety study and halted early based on safety data. The abstract does not address mismatch between ischemic damage timeline and alteplase\u2019s therapeutic effect as a mechanism for reduced functional independence in severe strokes.",
          "pmid": "18772447",
          "title": "The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines timing of oral anticoagulation initiation after atrial fibrillation\u2013related ischemic stroke and its impact on recurrent stroke and bleeding outcomes. It does not address alteplase (tPA), thrombolysis-related timelines, mismatch between ischemic damage and therapeutic effect, stroke severity\u2013specific functional independence, or recovery outcomes. Therefore it neither supports nor contradicts the proposed mechanism about alteplase\u2019s reduced functional independence recovery in severe strokes due to timeline mismatch.",
          "key_findings": "Early oral anticoagulation after AF-related ischemic stroke was associated with lower recurrent ischemic stroke risk (OR 0.72) without significant increase in intracranial hemorrhage, bleeding, mortality, TIA, or thrombosis, but with notable heterogeneity across studies.",
          "pmid": "41449918",
          "title": "Anticoagulation Timing After Stroke in Atrial Fibrillation: Evidence from a Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates nitroglycerin in animal ischemic stroke models and discusses timing, route, and hemodynamic effects of nitroglycerin, not alteplase. It does not address alteplase, thrombolysis, or the specific concept of a mismatch between ischemic damage and therapeutic effect timeline for alteplase in severe strokes, so it neither supports nor contradicts that proposed mechanism.",
          "key_findings": "Nitroglycerin did not significantly reduce infarct volume overall in experimental stroke models (20.2% reduction, 95% CI -1.52 to 52.7%, p=0.068). Subgroup analysis suggested greater efficacy when nitroglycerin was administered intracarotid to the ischemic territory at reperfusion. Authors hypothesize that direct delivery may reduce harmful systemic hypotension due to nitroglycerin\u2019s short half-life. No data on alteplase or thrombolytic treatment timelines are presented.",
          "pmid": "39182717",
          "title": "The effect of nitroglycerin treatment on cerebral ischaemia: A systematic review and meta-analysis of animal studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines dose-response effects of very early mobilization (a rehabilitation intervention) on functional outcomes after stroke, without discussing alteplase, thrombolysis, pharmacologic mechanisms, or any timeline mismatch between ischemic damage and alteplase\u2019s therapeutic effects. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "In a large stroke cohort, earlier and more frequent but shorter mobilization sessions within 24 hours of stroke onset were associated with higher odds of favorable 3\u2011month outcomes, whereas higher total daily minutes of mobilization reduced the odds of good outcome. Session frequency was more important than amount, after adjusting for age and baseline stroke severity.",
          "pmid": "26888985",
          "title": "Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the safety and tolerability of high-dose albumin therapy (and its interaction with alteplase/tPA) in acute ischemic stroke. It does not analyze timelines of ischemic damage versus therapeutic effect for alteplase, nor does it assess alteplase-related functional independence outcomes or how any temporal mismatch might lessen recovery in severe strokes.",
          "key_findings": "1) Pilot ALIAS trial tested escalating doses of 25% human albumin (0.34\u20132.05 g/kg) within 16 hours of stroke onset in patients with NIHSS \u22656. 2) Albumin was generally well tolerated; primary albumin-related adverse event was mild/moderate pulmonary edema in 13.4% of subjects, managed with diuretics. 3) In the subgroup also treated with tPA (42 patients), symptomatic intracranial hemorrhage occurred in 1/42, and tPA did not alter albumin\u2019s safety profile. 4) Abstract does not report functional independence outcomes or mechanistic data on alteplase\u2019s efficacy timeline relative to ischemic damage.",
          "pmid": "16809571",
          "title": "The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates UK-279,276 (a neutrophil inhibitory factor) in acute ischemic stroke using an adaptive design and reports no overall benefit, with a small post hoc signal in tPA-treated patients. It does not analyze alteplase\u2019s time-dependent efficacy, mismatch between ischemic damage and therapeutic timeline, or functional independence outcomes in severe strokes, so it neither supports nor contradicts the proposed mechanism about alteplase-specific temporal mismatch.",
          "key_findings": "UK-279,276 did not improve recovery in acute ischemic stroke overall (posterior probability of futility 0.89), leading to early termination; a post hoc analysis suggested a small additional improvement in Scandinavian Stroke Scale change in the subset cotreated with tPA; the study used a Bayesian adaptive dose-response design and treated patients within 6 hours of onset.",
          "pmid": "14563972",
          "title": "Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses immunomodulatory neuroprotection via partial MHC class II constructs in stroke models and the role of the spleen, but it does not mention alteplase, thrombolysis, treatment timelines, or any mismatch between ischemic damage and therapeutic effect. Therefore it neither supports nor conflicts with the proposed mechanism about alteplase\u2019s reduced functional independence recovery in severe strokes due to temporal mismatch.",
          "key_findings": "Partial MHC class II constructs (DRmQ/DRhQ) reduce motor deficits, infarct volume, and peri-infarct cell loss in murine and rat stroke models by modulating inflammation in the spleen and brain; these constructs dampen T cell cytokine expression and reduce neuroinflammation, satisfying certain STAIR translational criteria. No reference is made to alteplase, reperfusion therapy, or treatment\u2013injury timing relationships.",
          "pmid": "32237074",
          "title": "Spleen participation in partial MHC class II construct neuroprotection in stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates safety, tolerability, and pharmacokinetics of 2-iminobiotin as a neuroprotectant in large-vessel occlusion stroke treated with thrombectomy. It does not involve alteplase, does not analyze timelines of ischemic damage vs. therapeutic effect, and does not address functional independence recovery specifically in relation to alteplase use or timing. Therefore, it neither supports nor conflicts with the proposed mechanism about alteplase\u2019s reduced benefit due to a timing mismatch.",
          "key_findings": "2-iminobiotin was safe and well tolerated in ischemic stroke patients undergoing endovascular thrombectomy; serious adverse events were numerically fewer in the 2-IB group (30%) vs placebo (55%); functional and imaging outcomes (NIHSS, infarct volume, mRS) and mortality at 90 days were reported but in the context of 2-IB vs placebo, not alteplase or its therapeutic timeline.",
          "pmid": "40270284",
          "title": "Safety, Tolerability, and Pharmacokinetics of the Neuroprotectant 2-Iminobiotin in Patients With Large-Vessel Occlusion Ischemic Stroke Treated With Endovascular Thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses NXY-059, a neuroprotective agent for acute stroke, and does not address alteplase, its time-response relationship, or any mismatch between ischemic damage progression and therapeutic effect timeline. Therefore it provides no direct evidence for or against the proposed mechanism related to alteplase\u2019s reduced functional independence recovery in severe strokes.",
          "key_findings": "NXY-059, an intravenous nitrone-based free radical trapping agent, showed reductions in infarct volume and neurologic deficits in animal models, had predictable pharmacokinetics with renal elimination, and in Phase II and one Phase III trial showed favorable safety and a statistically significant reduction in disability after acute stroke compared with placebo. No information is provided on alteplase or on temporal mismatch between ischemic injury and therapeutic benefit.",
          "pmid": "16507608",
          "title": "NXY-059: review of neuroprotective potential for acute stroke.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Pre-existing platelet inhibition from antiplatelets may augment alteplase efficacy by promoting thrombus destabilization.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"destabilization\" OR \"antiplatelets\" OR \"inhibition\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 19,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses seizures and epilepsy after stroke, prognostic scores, biomarkers, and general considerations about drug\u2013drug interactions between antiseizure medications and anticoagulants/antiplatelets. It does not address alteplase, thrombolysis outcomes, or how pre-existing antiplatelet-induced platelet inhibition might modify alteplase efficacy or thrombus destabilization.",
          "key_findings": "Mentions that drug\u2013drug interactions between antiseizure medications and anticoagulants or antiplatelets influence treatment decisions in post-stroke epilepsy, but provides no data or discussion about alteplase use, thrombus stability, or modification of thrombolytic efficacy by antiplatelet therapy.",
          "pmid": "33619704",
          "title": "Seizures and Epilepsy After Stroke: Epidemiology, Biomarkers and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study evaluates the safety and efficacy of adding the factor XIa inhibitor milvexian on top of standard dual antiplatelet therapy after stroke/TIA. It does not compare outcomes between patients with and without pre-existing antiplatelet therapy, nor does it analyze how baseline platelet inhibition modifies alteplase efficacy or thrombus destabilization. Alteplase is not used or discussed, and no mechanistic interaction between antiplatelet therapy and thrombolysis is assessed.",
          "key_findings": "All participants received standard antiplatelet therapy (clopidogrel plus aspirin), and were randomized to different doses of milvexian versus placebo. Milvexian did not substantially reduce the composite of symptomatic ischemic stroke or covert brain infarct and did not meaningfully increase major bleeding. The trial addresses factor XIa inhibition on top of antiplatelet therapy, not the impact of pre-existing platelet inhibition on alteplase efficacy.",
          "pmid": "38101902",
          "title": "Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies the factor XIa inhibitor asundexian added to antiplatelet therapy for secondary prevention after non-cardioembolic stroke. It does not involve alteplase, thrombolysis, or examine how pre-existing platelet inhibition modifies alteplase efficacy or thrombus destabilization. Therefore it neither supports nor contradicts the specific proposed mechanism about antiplatelets augmenting alteplase efficacy.",
          "key_findings": "In patients with acute non-cardioembolic ischemic stroke already treated with antiplatelet therapy, adding asundexian (10, 20, or 50 mg) did not reduce the composite outcome of MRI-detected covert brain infarcts or recurrent symptomatic ischemic stroke compared with placebo and did not significantly increase major or clinically relevant non-major bleeding. No data on alteplase use, timing, or interaction with antiplatelet therapy in relation to thrombolytic efficacy are reported.",
          "pmid": "36063821",
          "title": "Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares edoxaban- versus VKA-based antithrombotic regimens after PCI in atrial fibrillation, focusing on bleeding and ischemic outcomes. It does not involve alteplase use, thrombolysis, or evaluation of how pre-existing platelet inhibition affects alteplase-mediated thrombus destabilization or efficacy. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Edoxaban plus a P2Y12 inhibitor was non-inferior to a VKA plus P2Y12 inhibitor and aspirin in terms of major or clinically relevant non-major bleeding, with no significant differences in ischemic events, in AF patients after PCI.",
          "pmid": "31492505",
          "title": "Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates bleeding safety of abelacimab versus rivaroxaban in atrial fibrillation patients with or without concomitant antiplatelet therapy. It does not involve alteplase, thrombolysis, or thrombus destabilization, nor does it assess how pre-existing platelet inhibition modifies alteplase efficacy. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In AZALEA-TIMI 71, abelacimab (a factor XI inhibitor) significantly reduced major or clinically relevant nonmajor bleeding compared with rivaroxaban both in patients on concomitant antiplatelet therapy and those not on antiplatelets; interaction p-values indicated consistent relative benefit regardless of antiplatelet use, with larger absolute bleeding risk reductions in those on antiplatelets. No data on alteplase, thrombolysis efficacy, or thrombus destabilization are presented.",
          "pmid": "40546068",
          "title": "Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aspirin\u2019s role as an antiplatelet agent, its drug\u2013drug interactions, and its use in secondary stroke prevention, but it does not address alteplase, thrombolysis, or whether pre-existing platelet inhibition modifies alteplase efficacy or thrombus destabilization. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Low-dose aspirin is recommended for secondary prevention of non-cardioembolic ischemic stroke and TIA; some NSAIDs can blunt aspirin\u2019s platelet inhibition via COX-1 competition; aspirin pharmacokinetics results in few clinically relevant PK drug\u2013drug interactions; co-administration with SSRIs may enhance platelet inhibition; aspirin remains a cornerstone therapy in cerebrovascular disease. No data on alteplase or thrombolytic efficacy are presented.",
          "pmid": "27765537",
          "title": "Aspirin, stroke and drug-drug interactions.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a broad review-style overview of stroke pharmacogenomics and mentions rtPA, antiplatelets, and warfarin in general terms, but it does not present any data or discussion about how pre-existing platelet inhibition affects alteplase efficacy or thrombus destabilization.",
          "key_findings": "The paper aims to review commonly used stroke drugs (rtPA acutely, antiplatelets and warfarin for secondary prophylaxis) within a pharmacogenetic framework, but provides no specific evidence about interactions between antiplatelet therapy and alteplase efficacy or thrombus stability.",
          "pmid": "19925046",
          "title": "Stroke pharmacogenomics.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes triflusal\u2019s antiplatelet effects and its clinical outcomes versus aspirin and placebo in various cardiovascular and surgical contexts, but it does not involve alteplase or any thrombolytic therapy, nor does it examine how pre-existing platelet inhibition modifies alteplase efficacy or thrombus destabilization during thrombolysis.",
          "key_findings": "Triflusal inhibits platelet arachidonic acid metabolism and shows clinical benefits in unstable angina, peripheral arteriopathy, and post-aortocoronary vein grafting compared with placebo or aspirin; it is associated with reduced bleeding versus aspirin in certain settings. No data are presented on alteplase use, thrombolytic therapy, or interaction between antiplatelet pretreatment and thrombolytic efficacy.",
          "pmid": "9617597",
          "title": "Triflusal.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses argatroban, a direct thrombin inhibitor, in the context of antithrombotic therapy and heparin-induced thrombocytopenia. It does not mention alteplase, fibrinolysis, or how pre-existing platelet inhibition might affect alteplase-mediated thrombus destabilization or efficacy.",
          "key_findings": "Argatroban is described as a reversible direct thrombin inhibitor with a short half-life, predictable anticoagulant response, and utility in heparin-induced thrombocytopenia and potentially acute coronary syndromes and PCI. No data are presented on antiplatelet agents, platelet inhibition, or interactions with alteplase.",
          "pmid": "11994559",
          "title": "Argatroban.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ximelagatran, a direct thrombin inhibitor, its efficacy and safety compared with warfarin/LMWH and in combination with aspirin, but does not involve alteplase, thrombolysis, or how pre-existing antiplatelet-induced platelet inhibition might modulate alteplase\u2019s thrombus-destabilizing effects.",
          "key_findings": "Ximelagatran is comparable to warfarin and LMWH for VTE prophylaxis and treatment, comparable to warfarin for stroke prevention in atrial fibrillation, and more effective than aspirin alone when combined with aspirin after myocardial infarction; bleeding complications are similar or lower than standard anticoagulants. No data on alteplase, thrombolysis, or interaction between antiplatelets and alteplase efficacy.",
          "pmid": "16511607",
          "title": "Ximelagatran.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aspirin and other antiplatelet agents for stroke prevention, focusing on overall reduction in major vascular events and dose\u2013efficacy/side-effect relationships. It does not examine alteplase use, thrombolysis outcomes, or how pre-existing antiplatelet therapy might modify alteplase efficacy or thrombus stability. Thus, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Aspirin reduces major vascular events by 19% overall and 13% in patients with ischemic cerebrovascular disease; no clear dose\u2013efficacy difference within 30\u20131300 mg, though higher doses increase side effects; other antiplatelet agents have no clear advantages over aspirin; platelet aggregation may still occur despite full COX-1 inhibition. No data are presented on interaction with alteplase or thrombolytic efficacy.",
          "pmid": "14592561",
          "title": "Aspirin and stroke prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on pharmacokinetic and pharmacodynamic interactions between clopidogrel and various traditional Chinese medicines, including changes in clopidogrel exposure, its active metabolite, and overall antiplatelet activity and bleeding risk. It does not involve alteplase, thrombolysis, or evaluate whether pre\u2011existing platelet inhibition alters alteplase efficacy or thrombus destabilization. Therefore it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Certain TCM herbs increase or decrease clopidogrel and its active metabolite levels; some herbs enhance or reduce clopidogrel\u2019s antiplatelet effect; Danggui may increase clopidogrel\u2011associated bleeding. No data are presented regarding alteplase, thrombolytic efficacy, or thrombus destabilization in the context of alteplase.",
          "pmid": "31471773",
          "title": "Interactions between clopidogrel and traditional Chinese medicine.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses CYP2C19 genotype-guided selection and efficacy of antiplatelet therapy (mainly clopidogrel) in neurovascular and neurointerventional settings, focusing on platelet inhibition levels and long-term thromboembolic outcomes. It does not address alteplase use, thrombolysis, or how pre-existing antiplatelet-induced platelet inhibition might modify alteplase efficacy or thrombus destabilization. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "1) Dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (commonly clopidogrel) is standard in neurovascular settings and neurointerventional procedures. 2) CYP2C19 no-function alleles lead to reduced clopidogrel activation and diminished platelet inhibition, associated with poorer clinical outcomes. 3) Genotype-guided antiplatelet therapy has improved outcomes in cardiovascular PCI settings; its utility and outcome data in neurointerventional procedures remain unclear. 4) The review aims to summarize evidence and gaps regarding CYP2C19-guided antiplatelet therapy in neurovascular disease but does not mention alteplase or thrombolytic efficacy.",
          "pmid": "39822142",
          "title": "CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how tocotrienol affects platelet function and aspirin resistance in stroke/TIA patients but does not involve alteplase use, thrombolytic efficacy, or thrombus destabilization outcomes. While it shows modulation of platelet inhibition, it provides no data on whether pre-existing platelet inhibition augments alteplase efficacy.",
          "key_findings": "In a randomized trial of 150 stroke/TIA patients on antiplatelet therapy, tocotrienol (400 mg and 800 mg daily) reduced the incidence of aspirin resistance in patients taking both aspirin and clopidogrel (from 40% in placebo to 9% in 400 mg TCT and 25% in 800 mg TCT, P = .03). No thrombolytic therapy, alteplase outcomes, or thrombus destabilization measures were reported.",
          "pmid": "32686874",
          "title": "Platelet function in stroke/transient ischemic attack patients treated with tocotrienol.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses variability in platelet inhibition with clopidogrel due to CYP2C19 polymorphisms and its impact on recurrent ischemic stroke risk, but it does not address alteplase use, thrombolysis outcomes, or how pre-existing antiplatelet-induced platelet inhibition might modify alteplase efficacy or thrombus destabilization.",
          "key_findings": "About 30% of patients have suboptimal platelet inhibition from antiplatelet agents, often due to variable clopidogrel response linked to CYP2C19 polymorphisms; high-dose clopidogrel can overcome suboptimal response in CYP2C19*2 carriers; FDA recommends considering genotyping before prescribing clopidogrel. No data on alteplase or interaction between antiplatelet therapy and thrombolytic efficacy are presented.",
          "pmid": "23618682",
          "title": "Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses clopidogrel resistance, variability in platelet inhibition, and associated thrombotic risk after coronary stenting, but it does not involve alteplase, thrombolysis, or any assessment of how pre-existing platelet inhibition might augment alteplase efficacy via thrombus destabilization. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Clopidogrel plus aspirin is standard to prevent post-stent thrombosis; there is significant variability and resistance in clopidogrel response; patients with high platelet reactivity or nonresponsiveness may have increased thrombotic risk; mechanisms of response variability are incompletely defined. No data are presented on alteplase or thrombolytic efficacy.",
          "pmid": "16611110",
          "title": "Clopidogrel resistance: implications for coronary stenting.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pharmacological interactions that modulate the effectiveness of aspirin and clopidogrel as antiplatelet agents, focusing on drug-induced resistance and attenuation of platelet inhibition. It does not examine thrombolytic therapy, alteplase, or whether pre-existing platelet inhibition alters alteplase efficacy or thrombus destabilization. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "1) Concomitant ibuprofen reduces the clinical benefit of aspirin, suggesting interference with aspirin\u2019s platelet inhibition. 2) Diclofenac minimally affects aspirin-induced inhibition of platelet aggregation. 3) Rofecoxib does not influence aspirin\u2019s effect. 4) Atorvastatin attenuates clopidogrel\u2019s platelet inhibition in vitro via CYP3A4 interactions, though post-hoc clinical analyses show no difference in outcomes between patients taking clopidogrel with CYP3A4-metabolized vs non-CYP3A4-metabolized statins. 5) The paper reviews mechanisms of drug-induced aspirin and clopidogrel resistance but does not address any interaction with alteplase or thrombolysis.",
          "pmid": "17008981",
          "title": "Possible mechanisms of drug-induced aspirin and clopidogrel resistance.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses dual antiplatelet therapy and addition of oral anticoagulants in acute coronary syndrome, focusing on bleeding and ischemic outcomes. It does not involve alteplase, thrombolysis, or platelet inhibition as a modifier of alteplase efficacy, nor does it address thrombus destabilization in the context of fibrinolytic therapy.",
          "key_findings": "Combination of new oral anticoagulants with dual antiplatelet therapy after ACS increases major bleeding (including intracranial) and may improve composite cardiovascular outcomes with low-dose rivaroxaban, but the net clinical benefit remains uncertain. No data are presented on alteplase use or its efficacy in relation to pre-existing antiplatelet therapy.",
          "pmid": "24136072",
          "title": "Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews prasugrel\u2019s antiplatelet efficacy and bleeding risk in ACS, mostly in the context of PCI, but does not evaluate its interaction with alteplase, thrombolysis, or thrombus destabilization in the setting of fibrinolytic therapy. There is no assessment of how pre-existing platelet inhibition affects alteplase efficacy.",
          "key_findings": "Prasugrel provides greater inhibition of platelet aggregation than clopidogrel (e.g., 74.8% vs 31.8% at 6 hours after loading in PRINCIPLE-TIMI 44) and reduces composite ischemic events vs clopidogrel in TRITON-TIMI 38, at the cost of increased major bleeding. No data are presented on use with alteplase or on how antiplatelet pre-treatment modifies thrombolytic efficacy.",
          "pmid": "19496635",
          "title": "Review of prasugrel for the secondary prevention of atherothrombosis.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "antiplat_rand",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Patients on antiplatelet agents might have thrombi with properties more amenable to alteplase-mediated clot lysis due to altered composition and reactivity.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (antiplatelet OR aspirin OR clopidogrel OR \"platelet inhibition\") AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"antiplatelet\" OR \"composition\" OR \"properties\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the safety and efficacy of adding the factor XIa inhibitor milvexian to standard dual antiplatelet therapy after stroke/TIA, but it does not examine or compare thrombus composition, alteplase responsiveness, or differential clot lysis in patients on antiplatelet agents. It reports clinical outcomes (recurrent ischaemic events, major bleeding) rather than mechanistic data about how antiplatelet therapy alters thrombus properties relevant to alteplase-mediated lysis.",
          "key_findings": "All participants received clopidogrel and aspirin; milvexian vs placebo showed no substantial reduction in the composite of symptomatic ischaemic stroke or covert brain infarction and no meaningful increase in major bleeding. The trial does not report on thrombus composition, reactivity, or response to alteplase, nor does it compare patients with and without antiplatelet therapy in terms of clot lysis characteristics.",
          "pmid": "38101902",
          "title": "Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antiplatelet therapy only in the broad context of cardiovascular disease prevention and treatment and does not discuss thrombus composition, reactivity, or response to alteplase-mediated clot lysis. There is no mechanistic or outcome data relating prior antiplatelet use to thrombus properties or alteplase effectiveness.",
          "key_findings": "Antiplatelet and anticoagulation therapies are listed as primary regimes for prevention and treatment of cardiovascular diseases, but no details are provided on how these therapies alter thrombus characteristics or influence susceptibility to thrombolysis with alteplase.",
          "pmid": "31553287",
          "title": "A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical outcomes (stroke recurrence) between PFO closure, antiplatelet therapy, and anticoagulation in cryptogenic stroke with PFO. It does not assess thrombus composition, reactivity, or differential responsiveness of thrombi to alteplase in patients on antiplatelet agents, nor does it involve fibrinolytic therapy or clot-lysis outcomes. Therefore it neither supports nor contradicts the proposed mechanism about antiplatelet-modified thrombi being more amenable to alteplase-mediated lysis.",
          "key_findings": "PFO closure plus antiplatelet therapy reduced recurrent stroke compared with antiplatelet therapy alone; anticoagulation showed a non-significant trend toward fewer strokes than antiplatelet therapy; PFO closure increased atrial fibrillation risk. No data were presented on thrombus characteristics, response to alteplase, or clot lysis mechanisms in relation to antiplatelet use.",
          "pmid": "28902593",
          "title": "Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses serum albumin\u2019s antiplatelet aggregation, anticoagulant, anti-inflammatory, and antioxidant properties and its association with cardiovascular diseases, but it does not address how prior antiplatelet therapy alters thrombus composition or affects alteplase-mediated clot lysis. No data are provided on thrombus characteristics, responsiveness to alteplase, or outcomes of thrombolytic therapy in patients on antiplatelet agents.",
          "key_findings": "Low serum albumin is associated with increased risk and worse prognosis in various cardiovascular diseases, and albumin has antiplatelet aggregation and anticoagulant activities. However, the abstract does not examine thrombus structure/composition, the effect of antiplatelet drugs on clot properties, or differential response to alteplase.",
          "pmid": "29680174",
          "title": "Human serum albumin in cardiovascular diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antiplatelet therapy as one of several stroke prevention options in cervical artery dissection but does not address thrombus composition, reactivity, or differential responsiveness to alteplase in patients on antiplatelet agents. There is no mechanistic or outcome data linking prior or concurrent antiplatelet use to altered thrombus properties or enhanced alteplase-mediated clot lysis.",
          "key_findings": "The review notes that stroke prevention in cervical artery dissection may involve anticoagulation or antiplatelet therapy, and other interventions such as stenting, thrombectomy, or angioplasty, but provides no data or discussion on how antiplatelet use affects thrombus characteristics or response to alteplase.",
          "pmid": "36082197",
          "title": "Cervical Artery Dissections: Etiopathogenesis and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antiplatelet drugs as beneficial in reducing cardiovascular events in diabetes but does not address thrombus composition, properties of clots in patients on antiplatelet therapy, or their responsiveness to alteplase-mediated lysis. No mechanistic or clinical data are presented about how prior antiplatelet use might alter thrombi to be more or less amenable to alteplase.",
          "key_findings": "Antiplatelet drugs, along with blood pressure control, lipid-lowering therapy, and ACE inhibition, significantly reduce the risk of cardiovascular events in patients with diabetes. The abstract does not discuss clot structure, thrombolysis, alteplase, or how antiplatelet therapy might change thrombus susceptibility to lysis.",
          "pmid": "12020339",
          "title": "Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cardiometabolic effects of long-chain omega-3 PUFAs, including antiplatelet properties, but it does not address thrombus composition under antiplatelet therapy or alteplase-mediated clot lysis, nor any interaction between antiplatelet agents and thrombolysis outcomes.",
          "key_findings": "LC \u03c9-3 PUFAs (EPA/DHA) have antiplatelet, anti-inflammatory, and vascular protective effects and modestly reduce cardiovascular death and myocardial infarction risk; they do not significantly affect stroke, all-cause mortality, or heart failure, and may increase atrial fibrillation risk. No data are presented on clot composition, thrombi properties, or alteplase responsiveness in patients on antiplatelet agents.",
          "pmid": "37031750",
          "title": "The Potential Cardiometabolic Effects of Long-Chain \u03c9-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a guideline/update on atrial fibrillation management and does not present primary data or mechanistic analysis regarding how prior antiplatelet therapy alters thrombus composition or responsiveness to alteplase-mediated lysis.",
          "key_findings": "The abstract only states that this is a focused update of AF management guidelines by AHA/ACC/HRS; it does not report findings on thrombus properties, antiplatelet therapy effects on clot composition, or alteplase responsiveness.",
          "pmid": "30686041",
          "title": "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses platelet reactivity in stroke, the megakaryocyte-platelet-haemostatic axis, and the general effectiveness of antiplatelet agents in secondary prevention. However, it does not examine or even mention thrombus composition under antiplatelet therapy, nor does it assess alteplase responsiveness or clot lysis characteristics in patients on antiplatelet agents. Thus it neither supports nor contradicts the specific mechanism that antiplatelet therapy yields thrombi more amenable to alteplase-mediated lysis.",
          "key_findings": "1) Platelet reactivity is accentuated in acute ischaemic stroke, particularly cortical stroke. 2) It is unclear whether enhanced platelet function is a cause or consequence of stroke. 3) Antiplatelet agents are effective in secondary but not primary prevention of stroke, possibly because accentuated platelet function is more relevant in cortical stroke. 4) No data are presented on thrombus properties under antiplatelet therapy or on alteplase-mediated clot lysis.",
          "pmid": "10512596",
          "title": "Platelets and stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antithrombotic therapies as part of atherosclerotic disease management but does not address how prior antiplatelet use alters thrombus composition or its susceptibility to alteplase-mediated lysis. No data or statements connect antiplatelet therapy to thrombus properties or thrombolytic efficacy.",
          "key_findings": "The abstract describes general pathogenesis of atherosclerotic disease, plaque rupture leading to thrombotic events, and the role of antithrombotic therapies in management, without mechanistic discussion of clot composition or response to alteplase in patients on antiplatelet agents.",
          "pmid": "37541708",
          "title": "Atherosclerotic Disease: Pathogenesis and Approaches to Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions antiplatelet drugs as part of treatment for intracranial atherosclerosis but does not address how prior or ongoing antiplatelet use affects thrombus composition, reactivity, or responsiveness to alteplase-mediated clot lysis. No data on thrombus properties, fibrinolysis, or alteplase outcomes are presented.",
          "key_findings": "Intracranial atherosclerosis causes thromboembolic ischemic events; risk factors include age, hypertension, and diabetes; treatment involves antiplatelet drugs, risk factor optimization, and sometimes intracranial angioplasty or stenting. No mention of alteplase or thrombus susceptibility to lysis.",
          "pmid": "24007975",
          "title": "Intracranial atherosclerosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates aspirin and other NSAIDs for dementia prevention and reports on bleeding and other adverse events, but it does not assess thrombus composition, thrombolysis, or alteplase-mediated clot lysis in patients on antiplatelet agents. Therefore, it neither supports nor contradicts the specific mechanistic claim about thrombus properties and responsiveness to alteplase.",
          "key_findings": "Low\u2011dose aspirin did not reduce dementia incidence compared with placebo but increased major bleeding and slightly increased mortality; non\u2011aspirin NSAIDs (celecoxib, naproxen, rofecoxib) did not prevent dementia and were associated with various adverse events. No data on thrombus structure, clot reactivity, or response to alteplase are reported.",
          "pmid": "32352165",
          "title": "Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract only mentions that antiplatelet agents (or anticoagulants) are used in cases of ischemia due to intracranial artery dissection, without any data or discussion on how prior or concurrent antiplatelet therapy alters thrombus composition, reactivity, or responsiveness to alteplase-mediated clot lysis.",
          "key_findings": "For cerebral ischemia from intracranial artery dissection, treatment includes anticoagulants or antiplatelet agents; no information is provided about thrombus properties under antiplatelet therapy or about alteplase efficacy in such patients.",
          "pmid": "24824740",
          "title": "Intracranial artery dissection.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the no-reflow phenomenon, its mechanisms, prognostic impact, and a list of potential therapies including antiplatelet agents in general. It does not address how prior or ongoing antiplatelet therapy alters thrombus composition or its susceptibility to alteplase-mediated fibrinolysis, nor does it discuss thrombolytic response or clot-lysis characteristics in patients on antiplatelet agents.",
          "key_findings": "No-reflow is mainly due to ischemic endothelial injury, with contributions from neutrophils, reactive oxygen species, coagulation cascade, and atherosclerotic/thromboembolism. Antiplatelet agents are mentioned only as one of several potential therapies for no-reflow, without mechanistic detail about thrombus properties or interaction with alteplase.",
          "pmid": "21712046",
          "title": "Coronary no reflow.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses clopidogrel resistance, its mechanisms, and clinical relevance, but does not address how prior or ongoing antiplatelet therapy alters thrombus composition or its susceptibility to alteplase-mediated clot lysis. There is no mention of thrombolysis, alteplase, or clot-lysis properties, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Some patients have impaired platelet response to clopidogrel (clopidogrel resistance), leading to persistently activated platelets and higher morbidity and mortality; various causes are implicated and alternative therapies are recommended. No data are presented on thrombus composition or response to alteplase.",
          "pmid": "19520658",
          "title": "[Clopidogrel resistance].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses perioperative management, pharmacology, and guidelines for antiplatelet therapy but does not mention thrombus composition, thrombolysis, or alteplase-mediated clot lysis. There is no data or discussion about how antiplatelet use might alter thrombus properties in a way that affects response to alteplase.",
          "key_findings": "The review covers: (1) the role of platelets in cardiovascular events, (2) use of antiplatelet agents as first-line therapy to prevent thrombotic events, (3) pharmacological and pharmacokinetic properties of antiplatelet drugs, and (4) strategies for perioperative continuation or discontinuation of these agents based on thrombotic versus bleeding risk. It does not address thrombus susceptibility to alteplase or clot lysis mechanisms.",
          "pmid": "24335397",
          "title": "Perioperative management of antiplatelet therapy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses unstable atherosclerotic plaques, plaque characteristics, and general preventive strategies including long-term antiplatelet therapy, but does not address how prior or ongoing antiplatelet use alters thrombus composition in a way that affects alteplase-mediated clot lysis or thrombolytic responsiveness.",
          "key_findings": "Ischemic strokes often arise from platelet-rich thrombi on atherosclerotic plaques; plaque vulnerability is linked to features such as intra-plaque hemorrhage, inflammation, cap thinning, ulceration, and abnormal motion; plaque stability can be improved via risk factor management and pharmacologic agents; patients with unstable plaques may need preventive treatment beyond long-term antiplatelet therapy. No data are presented on thrombus composition under antiplatelet therapy or on alteplase-mediated clot lysis.",
          "pmid": "14730254",
          "title": "The unstable plaque.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses indications, limitations, and new agents in antiplatelet therapy but does not address thrombus composition, reactivity, or responsiveness to alteplase-mediated clot lysis. There is no information about how prior or concurrent antiplatelet use affects thrombus susceptibility to alteplase.",
          "key_findings": "Antiplatelet therapy (including DAPT with aspirin and clopidogrel) is recommended for prevention of recurrent ischemic events; limitations include variable response to clopidogrel and delayed normalization of platelet function. The review focuses on pharmacologic properties and clinical data for newer antiplatelet drugs (prasugrel, ticagrelor, PAR-1 inhibitors). No mention is made of thrombolysis, alteplase, or clot-lysis characteristics.",
          "pmid": "25163316",
          "title": "[Antiplatelet drugs].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the central role of platelets in atherothrombosis and mentions that antiplatelet agents are effective in preventing and treating cardiovascular disease, but it does not address how prior antiplatelet therapy changes the composition or lytic susceptibility of formed thrombi, nor does it link antiplatelet use to altered responsiveness to alteplase.",
          "key_findings": "Platelets are key mediators in atherothrombosis, secreting substances involved in coagulation and inflammation; antiplatelet agents are briefly noted as efficacious in preventing and treating cardiovascular disease. No information is provided about thrombus composition under antiplatelet therapy or its amenability to alteplase-mediated clot lysis.",
          "pmid": "16438480",
          "title": "Platelets in atherothrombosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on anticoagulant-associated intracerebral hemorrhage, particularly warfarin-related ICH, predictors of hemorrhage, and reversal strategies. It mentions antiplatelet use only as a risk factor for hemorrhage when combined with anticoagulation, and does not address thrombus composition, properties of clots under antiplatelet therapy, or responsiveness of such thrombi to alteplase-mediated clot lysis.",
          "key_findings": "Antiplatelet use in addition to anticoagulation is listed as a predictor of anticoagulant-associated intracerebral hemorrhage; no data are presented on thrombus composition, reactivity, or alteplase-mediated clot lysis in patients on antiplatelet agents.",
          "pmid": "21207349",
          "title": "Anticoagulant-associated intracerebral hemorrhage.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Stroke Type: TACI (Total Anterior Circulation Infarct)",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "TACI strokes are frequently complicated by larger infarct zones and necessitate rapid recanalization to avert severe outcomes.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Stroke Type: TACI (Total Anterior Circulation Infarct)\" AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"recanalization\" OR \"necessitate\" OR \"complicated\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "Stroke Type: TACI (Total Anterior Circulation Infarct)",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Variability in collateral circulation could impact regenerative therapy success among stroke subtypes.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Stroke Type: TACI (Total Anterior Circulation Infarct)\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"regenerative\" OR \"variability\" OR \"circulation\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "Stroke Type: TACI (Total Anterior Circulation Infarct)",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "TACI's dense clot burden might be less responsive to alteplase alone, requiring alternative or combinational therapeutic strategies.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Stroke Type: TACI (Total Anterior Circulation Infarct)\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"combinational\" OR \"alternative\" OR \"therapeutic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Older age correlates with elevated comorbidities and reduced resilience to ischemic injury, complicating recovery.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"age\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"comorbidities\" OR \"complicating\" OR \"resilience\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 6,
      "conflict_count": 0,
      "neutral_count": 14,
      "support_percentage": 30.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.3,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports a stroke thrombolysis trial including older adults (median age 74) but does not analyze outcomes by age, comorbidity burden, or resilience to ischemic injury. It neither examines nor discusses how older age or comorbidities affect recovery or response to ischemic injury, so it does not provide direct evidence for or against the proposed mechanism.",
          "key_findings": "Randomized trial (AcT) comparing tenecteplase vs alteplase in 1600 acute ischemic stroke patients \u226518 years; median age 74. Primary outcome (mRS 0\u20131 at 90\u2013120 days) showed non-inferiority of tenecteplase vs alteplase (36.9% vs 34.8%; risk difference 2.1%, 95% CI \u22122.6 to 6.9). Rates of symptomatic intracerebral hemorrhage (3.4% vs 3.2%) and 90-day mortality (15.3% vs 15.4%) were similar. No age-stratified or comorbidity-resilience analyses were presented.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that short-term mortality after status epilepticus is primarily related to increasing age and medical comorbidities, which aligns with the proposed mechanism that older age is associated with elevated comorbidities and reduced resilience to ischemic/acute injury, complicating recovery.",
          "key_findings": "Short-term mortality after status epilepticus is 10\u201315% and is 'primarily related to increasing age, underlying etiology, and medical comorbidities.'",
          "pmid": "38117319",
          "title": "Status epilepticus in the ICU.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology of stroke with an aging population and focuses on neuroprotective strategies and clinical/preclinical advances. It does not address how older age influences comorbidities, resilience to ischemic injury, or recovery outcomes, nor does it provide mechanistic or clinical data linking age to reduced resilience or more complicated recovery.",
          "key_findings": "The abstract notes that the global population aged 65+ is growing and that stroke incidence is increasing, but it does not analyze age-related comorbidities, resilience to ischemic injury, or recovery trajectories; instead it reviews neuroprotective strategies and research initiatives like SPAN.",
          "pmid": "33144066",
          "title": "Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses astroglial pathophysiology across CNS diseases and notes that astroglial states vary with age and comorbidities, but it does not examine ischemic injury, resilience to ischemia, or recovery outcomes in older vs. younger individuals. It therefore does not directly test or demonstrate that older age correlates with elevated comorbidities and reduced resilience to ischemic injury.",
          "key_findings": "Astroglial pathophysiology is described as complex and context-specific, varying by disorder, disorder stage, comorbidities, age, and sex. Astrocytes can undergo reactive astrogliosis, atrophy, degeneration, death, or aberrant disease-driving changes across multiple CNS diseases. However, the abstract does not provide data or specific claims about how aging or comorbidities alter resilience to ischemic injury or recovery.",
          "pmid": "37828019",
          "title": "Astrocytes in human central nervous system diseases: a frontier for new therapies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of HIIT versus MICT on cardiorespiratory fitness and walking capacity in people with poststroke gait dysfunction. It reports a mean age but does not analyze outcomes by age, comorbidity burden, or resilience to ischemic injury, nor does it examine how older age affects recovery processes. Therefore, it does not provide direct evidence for or against the proposed age-related mechanism.",
          "key_findings": "In a 24-week randomized trial of 47 poststroke participants (mean age 62\u00b111 years), HIIT led to greater improvements in VO2peak than MICT (mean difference 3.2 mL\u00b7kg\u207b\u00b9\u00b7min\u207b\u00b9; P<0.001), while changes in 6-minute walk distance were similar between groups. HIIT also improved ventilatory anaerobic threshold more than MICT. No age-stratified or comorbidity-related analyses were reported.",
          "pmid": "37947080",
          "title": "Effect of High-Intensity Interval Training and Moderate-Intensity Continuous Training in People With Poststroke Gait Dysfunction: A\u00a0Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The mechanism proposes that older age is associated with elevated comorbidities and worse recovery from ischemic injury (reduced resilience/poorer outcomes). The abstract explicitly states that outcomes between age groups tend to be worse for older compared to younger adults with community-acquired pneumonia and notes that disadvantaged populations have more comorbidities leading to more severe CAP. While it does not directly mention ischemic injury, it supports the broader idea that older adults with more comorbidities have worse clinical outcomes, consistent with reduced resilience and more complicated recovery.",
          "key_findings": "1) Disadvantaged populations, including African-Americans, have more comorbidities which predispose them to more severe community-acquired pneumonia.\n2) Outcomes between age groups tend to be worse for older compared to younger adults with CAP.\n3) Older adults are highlighted as a particularly vulnerable group with significant disease burden and worse outcomes.",
          "pmid": "33470665",
          "title": "Pneumonia in older adults.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns genetic and hormonal determinants and consequences of PCOS and does not address age-related comorbidities, resilience to ischemic injury, or recovery from ischemia. It provides no data on age, ischemic events, or how comorbidities modify ischemic tolerance, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Mendelian randomization studies suggest obesity, testosterone, fasting insulin, SHBG, menopause timing, male-pattern balding, and depression may causally influence PCOS; PCOS may increase estrogen receptor\u2013positive breast cancer risk, decrease endometrioid ovarian cancer risk, and has no direct causal effect on type 2 diabetes, coronary heart disease, or stroke. Age-related ischemic resilience is not discussed.",
          "pmid": "34669940",
          "title": "Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on cardiometabolic and hormonal profiles of women with PCOS who are peri- or postmenopausal, not on age-related resilience to ischemic injury or recovery outcomes. Although it reports increased prevalence of myocardial infarction and stroke in older women with PCOS, it does not examine how older age itself, comorbidity burden, or reduced ischemic resilience affects recovery from ischemic injury. Thus it neither directly supports nor contradicts the proposed mechanism about aging, comorbidities, and ischemic recovery.",
          "key_findings": "In peri- and postmenopausal women with PCOS versus controls, the meta-analysis found: (1) persistent hyperandrogenism; (2) higher BMI, waist circumference, insulin resistance, diabetes risk, and some adverse lipid changes; (3) increased odds of hypertension, myocardial infarction, and stroke; (4) many cardiometabolic differences attenuated when BMI was matched, suggesting obesity is a major driver. The study did not assess resilience to ischemic injury, recovery after ischemic events, or age-specific effects on ischemic outcomes.",
          "pmid": "37353908",
          "title": "PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on post-stroke depression, its prevalence, and its association with functional outcomes after stroke, controlling for factors such as age and comorbidities. It does not analyze how older age per se relates to comorbidities or to reduced resilience to ischemic injury, nor does it examine age-related differences in recovery. Age and comorbidities are only covariates, not the mechanistic focus.",
          "key_findings": "Post-stroke depression (PSD) is common in the first three months after stroke (prevalence ranges 10.4\u201335.5% depending on time point). Across 21 non-experimental studies, PSD is significantly associated with poorer functional outcomes (dependence, activities of daily living, physical and cognitive function) from one month to five years post-stroke, even after adjusting for age, comorbidities, and stroke severity. Treatment of depression is associated with improved functional outcomes.",
          "pmid": "39173005",
          "title": "Association between post-stroke depression and functional outcomes: A systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly lists older age and vascular comorbidities as key risk factors for post-stroke cognitive impairment and dementia, implying that increased age (with associated comorbidities) is linked to worse outcomes after ischemic injury. While it does not directly discuss biological resilience to ischemic injury, it clearly connects older age and comorbid vascular disease with more complicated recovery manifesting as higher risk of vascular cognitive impairment and dementia.",
          "key_findings": "The abstract states that 25\u201330% of ischemic stroke survivors develop vascular cognitive impairment or dementia and identifies risk factors as including 'older age' and 'vascular comorbidities.' It further notes that dementia after stroke is multifactorial and that controlling vascular disease risk factors is essential to reduce the burden of cognitive dysfunction after stroke.",
          "pmid": "26806700",
          "title": "Stroke injury, cognitive impairment and vascular dementia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses HFpEF, comorbidities, and mouse models but does not address age-related differences in comorbidities, resilience to ischemic injury, or recovery. It focuses on diagnostic criteria and translational validity of HFpEF models rather than mechanisms linking older age to increased comorbid burden or reduced ischemic resilience.",
          "key_findings": "HFpEF is multifactorial with frequent non-cardiac comorbidities; new clinical scores (HFA-PEFF, H2FPEF) standardize diagnosis; most mouse HFpEF models do not fully meet clinical HFpEF criteria; a more complex, human-like modeling approach is needed. Age is mentioned as a recorded parameter but no age-related mechanistic results are provided.",
          "pmid": "34414416",
          "title": "Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly identifies advanced age and multiple chronic vascular comorbidities as key patient-specific risk factors for perioperative ischemic stroke and notes that the rising prevalence is driven by an aging, comorbidity-burdened population undergoing high-risk surgery. This supports the mechanistic idea that older age is linked to elevated comorbidities that worsen outcomes from ischemic injury, although it does not directly measure reduced biological resilience or recovery after stroke.",
          "key_findings": "1) The prevalence of perioperative stroke is rising, 'primarily driven by an aging surgical population burdened by multiple chronic vascular conditions.' 2) 'Key patient-specific risks include advanced age, recent cerebrovascular events, atrial fibrillation, carotid stenosis, and chronic cardiovascular comorbidities.' 3) Perioperative stroke is associated with substantial morbidity, disability, and mortality, implying worse outcomes in the high-risk, older, comorbid population.",
          "pmid": "40444359",
          "title": "Perioperative Stroke: Mechanisms, Risk Stratification, and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effectiveness of community-based complex interventions in older adults, stratified by frailty, focusing on independence outcomes. It does not examine how older age itself relates to comorbidity burden or biological resilience to ischemic injury, nor does it analyze recovery from ischemic events. Frailty is used as a categorization variable but no mechanistic data are presented about comorbidities, ischemic injury, or biological resilience, so the proposed mechanism is neither supported nor contradicted.",
          "key_findings": "The review and network meta-analysis of 129 RCTs (74,946 participants, mean age 65+) found that certain multifactorial community-based interventions (e.g., combinations including multidomain assessment/management, medication review, nutrition, exercise, ADL training) may help sustain independence (living at home, IADLs, PADLs) in older adults, though most evidence is low or very low certainty. Frailty stratification was attempted but few studies per comparison impeded evaluation of frailty as a moderator. No data are reported on comorbidity burden, ischemic injury, or biological resilience related to age.",
          "pmid": "39252602",
          "title": "Community-based complex interventions to sustain independence in older people, stratified by frailty: a systematic review and network meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on the effect of sacubitril/valsartan on all-cause and cause-specific hospitalizations in heart failure and examines effect modification by left ventricular ejection fraction, not by age, comorbidity burden, or resilience to ischemic injury. Although it notes that many patients are older with multiple comorbidities, it does not analyze outcomes stratified by age or comorbidity status, nor does it discuss ischemic injury resilience. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Sacubitril/valsartan reduced all-cause hospitalizations compared with renin-angiotensin system inhibitors in 13,194 chronic heart failure patients; benefit was driven mainly by reductions in cardiac and pulmonary hospitalizations and was more evident in patients with LVEF <60%. The cohort is described as including many older patients with multiple comorbidities, but no age- or comorbidity-specific outcome analyses are reported.",
          "pmid": "39210725",
          "title": "Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract notes that age and sex modify the risk\u2013benefit profile of carotid endarterectomy but does not describe how older age affects comorbidities, resilience to ischemic injury, or recovery from ischemic events. It neither quantifies age-related differences in complication rates nor links age to reduced resilience or more complex recovery, so it does not directly support or contradict the proposed biological mechanism.",
          "key_findings": "Age and sex are said to modify the simple rule for surgery based on stenosis severity, and a graphical procedure is proposed to improve patient selection. However, no specific data or mechanistic explanation is provided about older age being associated with elevated comorbidities, reduced resilience to ischemic injury, or more complicated recovery.",
          "pmid": "9593407",
          "title": "Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract notes that atrial fibrillation prevalence increases with age and number of cardiovascular comorbidities, but it does not discuss resilience to ischemic injury, recovery from ischemia, or age-related differences in ischemic outcomes. Thus it does not directly address the proposed mechanism about reduced resilience to ischemic injury complicating recovery in older adults.",
          "key_findings": "The abstract states that atrial fibrillation is the most common sustained cardiac rhythm disorder and that its prevalence increases with increasing age and the number of cardiovascular comorbidities. It also notes an association with complications such as increased risk of stroke, but does not examine age-related resilience to ischemic injury or recovery.",
          "pmid": "27159789",
          "title": "Atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions that HFpEF involves multiple co-morbidities and references an algorithm that includes elderly age >60 as a component, but it does not specifically address how older age alters resilience to ischemic injury or how that affects recovery. There is no direct data or discussion on ischemic injury tolerance or recovery outcomes by age.",
          "key_findings": "HFpEF is complex and heterogeneous with multiple co-morbidities; phenotype clusters are defined by the number and types of co-morbidities; the H2FPEF diagnostic algorithm includes elderly age >60 among its criteria. No explicit connection is made between older age, ischemic injury resilience, and recovery.",
          "pmid": "39844745",
          "title": "State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on treatment modalities (catheter-directed therapies vs systemic anticoagulation/thrombolysis) and their outcomes in acute pulmonary embolism. It does not analyze age-related differences, comorbidity burden, or resilience to ischemic injury, nor does it stratify results by age or comorbidity. Therefore, it neither supports nor contradicts the proposed mechanism about older age, comorbidities, and reduced resilience to ischemic injury.",
          "key_findings": "One small RCT of ultrasound-augmented catheter-directed thrombolysis versus systemic heparin alone in intermediate-risk PE showed no clear differences in 90-day all-cause mortality, major or minor haemorrhage, recurrent PE, or length of hospital stay; no trials were found for high-risk PE or catheter embolectomy. Age and comorbidity effects on outcomes or ischemic resilience were not examined.",
          "pmid": "35938605",
          "title": "Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "low",
          "reasoning": "The abstract states that right ventricular outflow tract dysfunction in repaired tetralogy of Fallot leads to increasing morbidity and mortality with advancing age and mentions emerging evidence on the roles of comorbidities, which is directionally consistent with the proposed mechanism that older age is associated with more comorbidities and worse outcomes. However, it does not explicitly discuss reduced resilience to ischemic injury or directly analyze age\u2013comorbidity\u2013injury relationships, so the support is indirect.",
          "key_findings": "1) Right ventricular outflow dysfunction in repaired tetralogy of Fallot leads to increasing rates of morbidity and mortality with advancing age. 2) The statement reviews emerging evidence on the roles of comorbidities and their impact on quality of life in this aging population.",
          "pmid": "39569497",
          "title": "Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism states that older age is associated with more comorbidities and reduced resilience to ischemic injury, complicating recovery. The abstract explicitly notes that age, prestroke functional status, and comorbidities explain many differences in stroke severity, functional outcomes, and mortality between men and women, implying that greater age and comorbidity burden are linked to worse outcomes and recovery. This aligns with the mechanism, although the abstract does not detail biological resilience per se.",
          "key_findings": "The abstract states that prior observations of worse outcomes in women after stroke are now understood to be largely explained by age, prestroke functional status, and comorbidities, which account for differences in stroke severity, functional outcomes, and mortality. It also highlights that age and certain comorbid conditions (e.g., hypertension, atrial fibrillation) have greater impact on women\u2019s stroke risk and outcomes.",
          "pmid": "32224757",
          "title": "Stroke in Women.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Age-related metabolic changes may modify drug pharmacokinetics, influencing alteplase's clinical benefits.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"age\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"pharmacokinetics\" OR \"influencing\" OR \"metabolic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates efficacy and safety of the factor XIa inhibitor milvexian for secondary stroke prevention, including dose\u2013response relationships, but it does not analyze or discuss age-related metabolic changes, pharmacokinetics, or how these might modify drug benefits. Although patient age is reported (median 71 years), there is no stratification, PK analysis, or interaction assessment by age or metabolic status, and the drug studied is milvexian, not alteplase.",
          "key_findings": "Phase 2 trial of milvexian versus placebo in patients \u226540 years with recent non-cardioembolic ischaemic stroke or TIA; median age 71. Various milvexian doses showed no significant dose\u2013response benefit on the composite of symptomatic ischaemic stroke or covert brain infarct at 90 days, and no clear dose\u2013response in major bleeding. The study does not report pharmacokinetic data, age-stratified efficacy or safety, or any analysis of how age-related metabolic changes influence drug effects.",
          "pmid": "38101902",
          "title": "Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns age-related metabolic changes altering alteplase pharmacokinetics and clinical benefit. This abstract evaluates apixaban (not alteplase) in hemodialysis patients, focusing on renal failure\u2013related pharmacokinetics and clinical outcomes, without analyzing age-related metabolic effects or alteplase. Therefore, it neither supports nor conflicts with the specified mechanism.",
          "key_findings": "In hemodialysis patients with atrial fibrillation, apixaban (5 mg or 2.5 mg BID) showed similar rates of major/clinically relevant nonmajor bleeding and stroke/systemic embolism compared with warfarin, with high overall bleeding rates and substantial pharmacokinetic variability. The study assessed apixaban exposure (AUC, trough and peak concentrations) and found overlap between patients with and without bleeding events. No data on alteplase, age-related metabolic changes, or their impact on alteplase pharmacokinetics or benefit were presented.",
          "pmid": "36335914",
          "title": "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses coffee consumption and cardiometabolic health, including age-related aspects and biological mechanisms, but does not mention alteplase, drug pharmacokinetics, or how age-related metabolic changes alter the pharmacokinetics or clinical benefits of alteplase or any comparable thrombolytic. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Coffee consumption is associated with reduced risks of type 2 diabetes, chronic kidney disease, metabolic syndrome, non-alcoholic fatty liver disease, some cardiovascular outcomes, and all-cause mortality, with effects generally consistent across age, sex, regions, and coffee subtypes. The mechanisms proposed involve antioxidative, anti-inflammatory, lipid-modulating, insulin-sensitizing, and thermogenic effects. No data are presented on drug metabolism, pharmacokinetics, or age-modified response to alteplase or other drugs.",
          "pmid": "38963648",
          "title": "Coffee consumption and cardiometabolic health: a comprehensive review of the evidence.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a practical guideline on NOAC use in atrial fibrillation and, although it mentions pharmacokinetics and special situations, it does not discuss age\u2011related metabolic changes or their impact on drug pharmacokinetics or clinical benefit of alteplase specifically.",
          "key_findings": "The guide covers 20 topics related to non\u2011vitamin K antagonist oral anticoagulants (NOACs), including pharmacokinetics, drug\u2013drug interactions, renal and hepatic impairment, bleeding management, and procedural management, but does not address age-related metabolic changes or alteplase pharmacokinetics or outcomes.",
          "pmid": "29562325",
          "title": "The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pharmacokinetics of losartan and its metabolite, including the lack of clinically significant age effects on losartan exposure. The proposed mechanism concerns age-related metabolic changes altering alteplase pharmacokinetics and clinical benefit. The abstract does not mention alteplase or thrombolytic therapy, nor does it examine age-related pharmacokinetic effects in a way that is generalizable to alteplase specifically, so it neither supports nor conflicts with the proposed alteplase-focused mechanism.",
          "key_findings": "Losartan is rapidly absorbed; about 14% is converted to active metabolite E3174 with a 6\u20139 hour half-life. Pharmacokinetics are linear and not substantially changed with repeated dosing. There are no clinically significant effects of age, sex, or race on losartan pharmacokinetics, and no dosage adjustment is needed in patients with mild hepatic impairment or various degrees of renal insufficiency. The drug is mainly metabolized by CYP3A4, 2C9, and 2C10.",
          "pmid": "16029066",
          "title": "Clinical pharmacokinetics of losartan.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates safety and efficacy of aficamten in nonobstructive hypertrophic cardiomyopathy, including dose adjustment based on ejection fraction, but does not analyze age-related metabolic changes, pharmacokinetics, or their influence on drug response. No pharmacokinetic data, age-stratified effects, or metabolic modifiers of drug response are reported, and the drug under study is aficamten, not alteplase.",
          "key_findings": "Open-label phase 2 trial of aficamten (5\u201315 mg daily) in 41 patients with symptomatic nonobstructive HCM showed: 55% improved \u22651 NYHA class and 29% became asymptomatic at 10 weeks; NT-proBNP decreased by 56% and hs-cTnI by 22%; modest mean LVEF reduction (~5.4%, with three patients transiently <50% LVEF that normalized after washout); one fatal arrhythmia in a patient with prior aborted sudden cardiac death. No data on age-related pharmacokinetics, metabolic changes, or alteplase.",
          "pmid": "38493832",
          "title": "Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies pharmacokinetics, pharmacodynamics, safety, and efficacy of sacubitril/valsartan versus enalapril in a pediatric population with heart failure, not alteplase. Although it involves age (children) and drug PK/PD, it does not examine age-related metabolic changes across an age spectrum nor their impact on alteplase pharmacokinetics or clinical benefit. Therefore it neither supports nor contradicts the proposed mechanism about age-related metabolic effects on alteplase.",
          "key_findings": "In children aged 1 month to <18 years with heart failure and LV systolic dysfunction, sacubitril/valsartan was not superior to enalapril on a 52-week global rank clinical endpoint. Both treatments led to clinically meaningful improvements in functional status and NT-proBNP, with similar adverse event rates and acceptable safety for sacubitril/valsartan. Pharmacokinetic/pharmacodynamic evaluation was performed but not linked to age-related metabolic changes affecting alteplase.",
          "pmid": "39319469",
          "title": "Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the safety and efficacy of risdiplam in infants with spinal muscular atrophy and describes age/weight-based dosing and pharmacokinetic-guided dose adjustments. It does not analyze age\u2011related metabolic changes, their impact on pharmacokinetics, or how such changes might modify clinical benefits of any drug (including alteplase). There is no discussion of alteplase or of age-related pharmacokinetic\u2013pharmacodynamic relationships.",
          "key_findings": "Risdiplam was given orally once daily with age/weight-based dosing and PK-guided adjustments in infants with type 1 SMA; after 24 months, 44% could sit unsupported for at least 30 s, with no infants able to stand or walk alone. Safety events included frequent respiratory infections and pneumonia. No data on age-related metabolic changes, no analysis of how such changes alter drug pharmacokinetics, and no mention of alteplase.",
          "pmid": "36244364",
          "title": "Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses brivaracetam\u2019s general pharmacokinetic profile and its effectiveness/tolerability in various age groups, including the elderly, but it does not examine age-related metabolic changes, their impact on drug pharmacokinetics, or how such changes might modify clinical benefits. No data on age-stratified pharmacokinetics or altered exposure/response with age are presented.",
          "key_findings": "Brivaracetam is described as having a favorable pharmacokinetic profile, rapid brain penetration, and few drug\u2013drug interactions, with efficacy and safety demonstrated in multiple trials. Evidence from clinical practice indicates effectiveness and tolerability in specific populations such as the elderly (\u226565 years), children, and patients with comorbidities. However, there is no analysis of age-related metabolic changes or their influence on brivaracetam\u2019s pharmacokinetics or clinical benefits.",
          "pmid": "38811492",
          "title": "Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports safety, efficacy, and some pharmacodynamic/structural outcomes of aficamten over 48 weeks in adults with obstructive hypertrophic cardiomyopathy, but it does not analyze age-related metabolic changes, pharmacokinetics, or how age modifies clinical benefit. Mean age is reported descriptively, with no age-stratified PK or clinical outcome analysis, so it neither supports nor contradicts the proposed mechanism about age-related metabolic modification of alteplase pharmacokinetics and benefits.",
          "key_findings": "Open-label extension of aficamten (not alteplase) showed: sustained reductions in LVOT gradients, NYHA class improvement in 82% of patients, improved KCCQ scores, reductions in LV wall thickness, LA volume index, E/e', and cardiac biomarkers; aficamten was generally well tolerated with only 2 transient asymptomatic LVEF reductions and no new-onset atrial fibrillation; mean age of participants was 59.7 years, but no pharmacokinetic or outcome analyses by age were presented.",
          "pmid": "40540987",
          "title": "Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates eculizumab (a complement C5 inhibitor) in adolescents with generalized myasthenia gravis and reports clinical efficacy, safety, pharmacokinetics, and pharmacodynamics in this age group. The proposed mechanism concerns age\u2011related metabolic changes altering the pharmacokinetics and clinical benefit of alteplase, a different drug used for a different indication. The study does not investigate alteplase, age-related metabolic differences across age groups, or any link between aging, metabolism, and alteplase pharmacokinetics or outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Adolescents (12\u201317 years) with refractory AChR antibody\u2013positive generalized myasthenia gravis treated with eculizumab showed significant improvements in QMG and MG\u2011ADL scores over 26 weeks, with sustained terminal complement inhibition and only mild to moderate adverse events. Pharmacokinetics and pharmacodynamics of eculizumab were recorded but not related to age-related metabolic changes or to alteplase.",
          "pmid": "38810600",
          "title": "Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates HU6, a metabolic accelerator, in obese HFpEF patients, focusing on weight loss, body composition, functional capacity, and safety. It does not involve alteplase, thrombolytic therapy, or age-related changes in pharmacokinetics, nor does it examine how metabolic changes with aging alter the clinical benefits of alteplase.",
          "key_findings": "HU6 increased metabolism leading to modest but significant reductions in body weight, total fat mass, and visceral fat percentage over 19 weeks without muscle loss or significant improvements in peak VO2 or functional/biomarker outcomes; safety profile showed some serious adverse events deemed unrelated to treatment. No data on alteplase, age-related pharmacokinetics, or thrombolytic efficacy are presented.",
          "pmid": "40072462",
          "title": "Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke pharmacogenomics, conventional risk factors including age, and mentions rtPA (alteplase) among principle drugs, but it does not address age-related metabolic changes, pharmacokinetic alterations of alteplase, or how these might modify its clinical benefits. It remains at a general conceptual level and does not present mechanistic or empirical data relevant to the proposed pharmacokinetic mechanism.",
          "key_findings": "Age is highlighted as the strongest risk factor for stroke; pharmacogenetics is described as influencing drug response; rtPA is listed as a key acute stroke drug, but no data or discussion is provided on how age-related metabolic changes affect alteplase pharmacokinetics or outcomes.",
          "pmid": "19925046",
          "title": "Stroke pharmacogenomics.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age as a factor in prasugrel\u2019s benefit\u2013risk profile and mentions dose modifications in specific populations, but it does not address age-related metabolic or pharmacokinetic changes, nor alteplase or its clinical benefits. Thus, it does not provide evidence for or against the proposed pharmacokinetic mechanism involving alteplase.",
          "key_findings": "Prasugrel is more potent and consistent than clopidogrel; it reduces ischemic events but increases major bleeding risk, particularly in certain subgroups. The ideal population is described as patients without prior TIA/stroke, younger than 75 years, and weighing more than 60 kg. Dose modifications in specific populations are suggested to minimize bleeding risk. No data are presented on age-related metabolic changes affecting drug pharmacokinetics, and alteplase is not mentioned.",
          "pmid": "22906902",
          "title": "Prasugrel.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related differences in rivaroxaban pharmacokinetics, not alteplase. While it notes that elimination time is longer in elderly patients, this is for a different drug and without analysis of clinical benefit changes related to these PK differences. Therefore it does not directly address whether age-related metabolic changes modify alteplase pharmacokinetics or its clinical benefits.",
          "key_findings": "Rivaroxaban has predictable pharmacokinetics; excretion is mainly renal; mean elimination time is 5\u20139 hours in younger vs. 11\u201313 hours in elderly; pharmacokinetics minimally influenced by sex and age; mild hepatic impairment does not significantly affect rivaroxaban PK/PD. No data on alteplase or its age-related pharmacokinetics or clinical effects.",
          "pmid": "28840739",
          "title": "[Rivaroxaban in high-risk patients].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports that age significantly influences tenecteplase clearance and initial volume of distribution and quantifies that age accounts for an additional 11% of clearance variability. However, it does not examine age-related metabolic changes in relation to alteplase pharmacokinetics or link these age effects to clinical benefits or outcomes with alteplase. The findings are about tenecteplase, not alteplase, and do not directly test or demonstrate that age-related metabolic changes modify alteplase\u2019s pharmacokinetics in a way that alters its clinical benefit.",
          "key_findings": "1) In 179 AMI patients treated with tenecteplase, body weight and age significantly influenced both clearance (CL) and initial volume of distribution (V1). 2) Total body weight explained 19% of variability in CL and 11% in V1; a 10 kg increase in body weight increased CL by 9.6 ml/min. 3) Age explained an additional 11% of variability in CL. 4) Tenecteplase showed biphasic disposition with prolonged half-lives and reduced clearance compared with alteplase, but the age effect on pharmacokinetics and its clinical implications are evaluated only for tenecteplase, not for alteplase.",
          "pmid": "12452736",
          "title": "Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the pharmacokinetics of sotalol, including that age has only slight and clinically unimportant effects on its bioavailability. It does not examine alteplase, nor does it evaluate how age-related metabolic changes modify alteplase pharmacokinetics or its clinical benefits. Therefore, it neither supports nor conflicts with the proposed mechanism for alteplase.",
          "key_findings": "Sotalol is completely absorbed, not metabolized, has near 100% bioavailability, and is renally excreted. Age and food have slight but unimportant effects on bioavailability. Plasma levels and half-life are related to renal function, not hepatic metabolism. No data are presented on alteplase or age-related changes in its pharmacokinetics or clinical effects.",
          "pmid": "2403731",
          "title": "Pharmacology, pharmacodynamics and pharmacokinetics of sotalol.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related differences in pharmacokinetics (longer half-life in elderly) for rivaroxaban, a direct factor Xa inhibitor, not alteplase. It does not evaluate how age-related metabolic changes modify alteplase pharmacokinetics or its clinical benefits, nor does it generalize these findings to alteplase or thrombolytics.",
          "key_findings": "In humans, rivaroxaban shows predictable anticoagulation with dose-proportional effects; half-life is 7\u201311 h in young vs 11\u201313 h in elderly subjects. Oral bioavailability is high (80\u2013100%) and not affected by food. No dose adjustment is deemed necessary across age, gender, or body weight in the studied indication.",
          "pmid": "21848931",
          "title": "Pharmacodynamic and pharmacokinetic basics of rivaroxaban.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses pharmacology, dosing, and adherence of NOACs in elderly patients, including the need to individualize doses and balance ischemic and bleeding risks with age. However, it does not mention alteplase, nor does it provide data on age-related metabolic changes altering pharmacokinetics or clinical benefits of alteplase specifically.",
          "key_findings": "Elderly atrial fibrillation patients have higher ischemic and bleeding risks; NOACs are available with dose-reduction criteria; correct dose identification and adherence are critical; once-daily dosing improves adherence without increasing bleeding risk. No discussion of alteplase or age-related pharmacokinetic changes affecting its clinical benefit.",
          "pmid": "33060545",
          "title": "Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract addresses age-related effects on pharmacokinetics, pharmacodynamics, efficacy, and safety, but for rivaroxaban, not alteplase. While it reports that age has at most a moderate, not clinically relevant effect on rivaroxaban clearance and clinical outcomes, this cannot be directly extrapolated to alteplase, so it neither supports nor contradicts the proposed alteplase-specific mechanism.",
          "key_findings": "In older adults, clinical pharmacology data show no clinically relevant effect of age on rivaroxaban pharmacokinetics and pharmacodynamics; population PK studies show a moderate but not clinically significant reduction in rivaroxaban clearance with age; phase 3 trials and real-world evidence demonstrate consistent efficacy and safety across age subgroups and do not require dose adjustment solely based on age.",
          "pmid": "29932775",
          "title": "Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "age",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Age-related shifts in vascular architecture and regulation affect alteplase's impact efficacy and safety profile.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"age\" AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"architecture\" OR \"regulation\" OR \"alteplase\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates overall efficacy and safety (functional outcomes, sICH, mortality) of intravenous thrombolysis beyond 4.5 hours but does not analyze age-related differences, vascular architecture, or regulatory changes, nor does it specifically assess alteplase\u2019s age-dependent impact. Mean age is reported only descriptively without stratified or mechanistic analysis, so it neither supports nor contradicts the proposed age-related vascular mechanism.",
          "key_findings": "In eight RCTs (1742 patients, mean age ~70 years), IV thrombolysis beyond 4.5 hours improved excellent and good functional outcomes versus standard care, increased symptomatic intracerebral hemorrhage, and did not significantly change 90-day mortality. Subanalyses compared imaging selection methods and alteplase vs tenecteplase, but no age-stratified or vascular-architecture-related analyses were reported.",
          "pmid": "39882605",
          "title": "Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age, cardiovascular disease, and other intrinsic factors in the context of thermoregulation and heat stress, but it does not mention alteplase, thrombolysis, stroke treatment, or any drug\u2013age interaction affecting alteplase efficacy or safety. Therefore it neither supports nor contradicts the proposed mechanism about age-related vascular changes modifying alteplase\u2019s impact.",
          "key_findings": "The review describes how morphology, heat adaptation, sex, age, diseases (including cardiovascular disease), and injuries influence deep body temperature regulation and autonomic heat loss responses during heat stress. It focuses on thermophysiology under heat stress, not on pharmacologic treatment or age-dependent vascular modulation of alteplase outcomes.",
          "pmid": "35679471",
          "title": "Human temperature regulation under heat stress in health, disease, and injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses microglia-mediated neuroinflammation as a target in cardiovascular diseases via autonomic nervous system changes, but does not mention alteplase, thrombolysis, age-related vascular architecture, or how age alters alteplase efficacy or safety. Thus it is only tangentially related to stroke/cardiovascular pathophysiology and does not provide evidence for or against age-related vascular shifts affecting alteplase\u2019s impact.",
          "key_findings": "Microglia, as CNS-resident macrophages, modulate synaptic and neuronal activity and are activated in various cardiovascular diseases (hypertension, myocardial infarction, ischemia/reperfusion injury). Regulation of microglial activity can alter the incidence and progression of these diseases, potentially via changes in autonomic nervous system activity. Microglia are proposed as neuroimmune modulators and therapeutic targets in cardiovascular disease.",
          "pmid": "35642214",
          "title": "Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ageing-related molecular pathways, endothelial homeostasis, and adverse vascular phenotypes leading to stroke and other CVD, but it does not mention alteplase, thrombolytic therapy, or age-related differences in alteplase efficacy or safety. Thus, it is related to vascular ageing in general but does not provide direct evidence about how age-related vascular changes modulate alteplase\u2019s impact.",
          "key_findings": "Age is a major risk factor for cardiovascular disease; environmental factors induce premature defects in mitochondrial function, insulin signaling, endothelial homeostasis, and redox balance; molecular pathways including FOXOs, AMPK, SIRT1, p66(Shc), JunD, and NF-kB are implicated in linking ageing, metabolism, and cardiovascular deterioration, fostering adverse vascular and cardiac phenotypes responsible for myocardial infarction, stroke, and heart failure.",
          "pmid": "26391109",
          "title": "Ageing, metabolism and cardiovascular disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses mitochondrial dysfunction, oxidative stress, and mitochondria\u2011targeted therapies in metabolic syndromes and aging in general, but does not mention vascular architecture or regulation, alteplase, thrombolysis, or age-related differences in alteplase efficacy or safety. Thus it neither supports nor contradicts the proposed vascular/alteplase mechanism.",
          "key_findings": "Mitochondrial dysfunction and oxidative stress are implicated in aging, cancer, neurodegenerative disease, metabolic syndrome, stroke, hypertension, and heart disease. The article reviews progress in understanding mitochondrial biology in these conditions and in developing lifestyle, pharmacologic, and mitochondria-targeted therapeutic strategies to reduce mitochondrial dysfunction and maintain mitochondrial quality.",
          "pmid": "27836629",
          "title": "Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses vitamin D, neuroprotection, and Parkinson\u2019s disease, but does not mention alteplase, thrombolysis, vascular architecture, or age-related vascular regulation. Therefore it does not provide evidence for or against age-related vascular effects on alteplase efficacy or safety.",
          "key_findings": "Vitamin D deficiency is common in Parkinson\u2019s disease, associated with disease severity, progression, and fall risk; its neuroprotective role is suggested, but evidence for benefit from supplementation is limited. No data are presented on vascular changes, alteplase, or thrombolytic treatment.",
          "pmid": "35334877",
          "title": "Vitamin D and Parkinson's Disease.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on genetic variants associated with blood pressure regulation and their effects on stroke risk. It does not address age-related changes in vascular architecture or regulatory shifts, nor how these age-related vascular changes might modify alteplase\u2019s efficacy or safety. There is no mention of alteplase, thrombolysis, or age-stratified vascular responses to therapy.",
          "key_findings": "Identification of rare and common genetic variants influencing blood pressure; enrichment of BP-associated variants in fetal active chromatin regions; suggestion of possible inverse causal effects of elevated systolic and diastolic BP on large artery stroke via Mendelian randomization; highlighting of candidate causal genes and therapeutic targets for BP, but no discussion of age-related vascular changes or alteplase response.",
          "pmid": "33230300",
          "title": "Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on age-related changes in the gut microbiota and the gut-brain axis in relation to neurological disorders, including ischemic stroke, but it does not address vascular architecture/regulation or alteplase, nor treatment efficacy or safety. Thus it is related to aging and stroke broadly but does not provide evidence for or against age-related vascular effects on alteplase response.",
          "key_findings": "Age-related shifts in gut microbiota composition are linked to neurological diseases and acute brain injuries such as ischemic stroke; microbiota-targeted therapies can modulate behavioral and immunological outcomes. The work centers on microbiota\u2013gut\u2013brain signaling pathways, not on vascular changes or alteplase treatment profiles.",
          "pmid": "38237031",
          "title": "The contribution of age-related changes in the gut-brain axis to neurological disorders.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on heat adaptation, exercise performance, and thermoregulatory and cardiovascular responses to heat in general. It does not involve alteplase, thrombolytic therapy, stroke treatment, or age-related vascular architectural/regulatory changes, so it cannot support or contradict the proposed alteplase-specific vascular mechanism.",
          "key_findings": "Heat adaptation over 7\u201314 days or longer improves exercise capacity and performance in the heat, lowers core temperature, helps maintain cardiovascular stability, enhances heat-loss pathways, and improves perceptual measures such as RPE and thermal sensation. These effects are regimen-dependent but unrelated to alteplase or age-related vascular changes.",
          "pmid": "27106556",
          "title": "The Effects of Heat Adaptation on Physiology, Perception and Exercise Performance in the Heat: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns guidelines for autophagy assay use and interpretation and does not address age-related vascular changes, vascular architecture/regulation, or alteplase efficacy/safety. There is no discussion of thrombolytic therapy or age-dependent vascular physiology.",
          "key_findings": "The paper provides methodological guidance on monitoring autophagy (assay selection, interpretation, and standardization) without mentioning vascular function, aging-related vascular shifts, or alteplase.",
          "pmid": "26799652",
          "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related changes in neuronal calcium regulation, oxidative stress, and neurodegeneration, but does not address vascular architecture, vascular regulation, or how aging alters the efficacy or safety profile of alteplase (a thrombolytic). Therefore it neither supports nor contradicts the proposed vascular-based mechanism for alteplase.",
          "key_findings": "Aging and neurodegenerative disorders compromise neuronal Ca2+ regulatory systems, leading to synaptic dysfunction, impaired plasticity, and neuronal degeneration; oxidative stress, altered energy metabolism, and aggregation of disease-related proteins disrupt Ca2+ homeostasis; alterations in Ca2+-regulating proteins in plasma membrane, ER, and mitochondria contribute to age-related neuronal dysfunction; genetic and environmental factors modulate these calcium-related changes. No data on vascular changes or alteplase response.",
          "pmid": "17328689",
          "title": "Calcium and neurodegeneration.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses mechanisms of endothelial senescence and vascular aging in general (e.g., arterial stiffness, calcification, endothelial dysfunction, molecular regulators) but does not mention alteplase, thrombolysis, or how age-related vascular changes alter alteplase\u2019s efficacy or safety. It is relevant background on vascular aging but provides no direct evidence for or against the proposed alteplase-specific mechanism.",
          "key_findings": "Vascular aging is associated with endothelial and smooth muscle cell dysfunction, arterial stiffness, calcification, atherosclerosis, and remodeling of the intima. Endothelial cell senescence is driven by complex networks involving Klotho, nitric oxide, FGF21, and SIRT family members. The review aims to delineate mechanisms of endothelial senescence and identify therapeutic targets for age-related vascular diseases, but it does not address drug response or alteplase.",
          "pmid": "40560245",
          "title": "Mechanisms of endothelial senescence and vascular aging.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses guidelines and methodological considerations for monitoring autophagy and related cellular processes. It does not address age-related vascular changes, vascular architecture or regulation, alteplase, or its efficacy/safety profile, so it neither supports nor contradicts the proposed physiological mechanism.",
          "key_findings": "The paper outlines updated guidelines for selecting and interpreting assays to study autophagy, emphasizes using multiple techniques and targeting multiple autophagy-related genes, and notes that many autophagy proteins also regulate other pathways such as apoptosis.",
          "pmid": "33634751",
          "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract analyzes alteplase efficacy and safety across different time windows after stroke onset, adjusting for baseline age but not examining how age-related vascular architecture or regulation specifically modifies alteplase\u2019s impact. No mechanistic data on vascular changes with aging or age-stratified differences in efficacy or hemorrhage risk are presented, so the proposed age-related vascular mechanism is neither supported nor refuted.",
          "key_findings": "1) Reperfusion after alteplase was associated with substantially improved 90-day functional outcome (common OR 7.7, 95% CI 4.6\u201312.8). 2) The beneficial effect of reperfusion was consistent across 4.5\u20136 h, 6\u20139 h, and wake-up stroke strata, with no significant interaction between time to randomization and benefit (P=0.63). 3) Symptomatic intracerebral hemorrhage rates in alteplase-treated patients were similar across time strata (5.9%, 7.1%, and 5.5%; Fisher P=0.91). 4) Age was included as an adjustment variable, and median ages were similar between reperfusion and non-reperfusion groups, but no age-stratified efficacy or safety analyses, nor vascular-architecture-related mechanisms, were reported.",
          "pmid": "33137171",
          "title": "Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aging, exosomes, and exosomal microRNAs in relation to neurovascular function and age-associated stroke, but it does not mention alteplase, thrombolysis, or how age-related vascular architecture or regulation changes alter alteplase\u2019s efficacy or safety profile. Therefore it neither supports nor contradicts the proposed alteplase-specific mechanism.",
          "key_findings": "Aging is described as a major non-modifiable risk factor for stroke; exosomes and their microRNA cargo regulate neurovascular function and are implicated in stroke initiation and progression; circulating microRNAs participate in cellular senescence and contribute to age-associated stroke. No data are presented on thrombolytic therapy, alteplase response, or age-related modulation of alteplase efficacy or safety.",
          "pmid": "33563154",
          "title": "Exosomes and Exosomal microRNAs in Age-associated Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on genetic risk loci and shared polygenic architecture for fibromuscular dysplasia and other cardiovascular diseases. It discusses genes and pathways related to actin cytoskeleton and intracellular calcium homeostasis in arterial cells, but does not address age-related changes in vascular architecture or regulation, nor does it evaluate how such age-related vascular shifts alter alteplase efficacy or safety.",
          "key_findings": "GWAS meta-analysis of fibromuscular dysplasia identified several risk loci (PHACTR1, LRP1, ATP2B1, LIMA1, SLC24A3), showed FMD has a polygenic basis, and that associated variants lie in arterial regulatory elements tied to actin cytoskeleton and calcium homeostasis. The study also reports genetic overlap between FMD and common cardiovascular traits (blood pressure, migraine, intracranial aneurysm, coronary artery disease). No data on age-related vascular changes or on alteplase effects are provided.",
          "pmid": "34654805",
          "title": "Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reviews age-dependent changes in cerebral small vessels (e.g., arterial stiffness, endothelial dysfunction, altered blood\u2013brain barrier and flow regulation) but does not mention alteplase, thrombolysis, or any data on how these vascular changes modify alteplase\u2019s efficacy or safety. Thus it is mechanistically relevant background but does not provide direct evidence for or against the proposed alteplase-related mechanism.",
          "key_findings": "Age-dependent processes in cerebral small vessel disease include arterial stiffness, vascular oxidative stress, low-grade systemic inflammation, gut dysbiosis, increased salt intake, endothelial dysfunction, impaired cerebral blood flow regulation, blood\u2013brain barrier disruption, neuroinflammation, and impaired glymphatic clearance. These mechanisms are linked to vascular cognitive impairment, intracerebral hemorrhage, and lacunar stroke, but no therapeutic impact of alteplase is discussed.",
          "pmid": "37864643",
          "title": "Cerebral Small Vessel Disease: a Review of the Pathophysiological Mechanisms.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses adult hippocampal neurogenesis and its age-related decline, focusing on neuronal generation and regulation in the brain. It does not mention vascular architecture, vascular regulation, alteplase, thrombolysis, or treatment efficacy/safety in relation to age, so it neither supports nor contradicts the proposed vascular mechanism.",
          "key_findings": "The study describes evidence for adult hippocampal neurogenesis in mammals, notes a decline of hippocampal neurogenesis during aging, and discusses broader questions about regulation and function of adult neurogenesis, including in humans. No vascular or alteplase-related data are presented.",
          "pmid": "30381404",
          "title": "Adult Hippocampal Neurogenesis: A Coming-of-Age Story.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract describes age-related endothelial dysfunction, oxidative stress, and inflammation, and notes that aging is an independent risk factor for vascular disease. However, it does not discuss alteplase, thrombolytic therapy, or how age-related vascular changes specifically modify alteplase\u2019s efficacy or safety profile. Thus, it is relevant to age-related vascular changes in general but does not provide direct evidence for or against the proposed alteplase-specific mechanism.",
          "key_findings": "Aging is associated with a gradual decline in endothelial regulation of cardiovascular homeostasis; age is an independent risk factor for cardiovascular diseases including stroke; oxidative stress and inflammation are highlighted as major contributors to age-related endothelial dysfunction; exercise can improve aging endothelial function by modulating oxidative stress and inflammatory processes.",
          "pmid": "23984434",
          "title": "Exercise and the aging endothelium.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related declines in physical work capacity, cardiac pump function, muscle strength, and heat tolerance, but it does not address vascular architecture or regulation in detail, nor does it mention alteplase, thrombolysis, or treatment efficacy/safety. Thus it neither supports nor contradicts the specific mechanism about age-related vascular changes modifying alteplase\u2019s profile.",
          "key_findings": "Aging is associated with reduced aerobic power, muscular strength and endurance, and heat tolerance; some loss can be mitigated by physical activity and lifestyle; even trained athletes show substantial age-related deterioration in cardiac pump function and muscle strength. The paper focuses on occupational implications and the paradox that older workers\u2019 productivity and safety are not greatly impaired.",
          "pmid": "10553515",
          "title": "Age and physical work capacity.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbprand",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Elevated BP may elevate hemorrhagic conversion risk post-thrombolysis.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"diastolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"thrombolysis\" OR \"hemorrhagic\" OR \"conversion\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension as a general modifiable risk factor for both ischemic and hemorrhagic stroke and as a target for stroke prevention, but it does not address blood pressure levels in the context of thrombolytic therapy or hemorrhagic conversion after thrombolysis specifically.",
          "key_findings": "Hypertension is identified as a common, modifiable risk factor that increases overall stroke risk and is a target for prevention strategies, but no data or statements are provided about elevated blood pressure influencing hemorrhagic transformation risk following thrombolysis.",
          "pmid": "28154098",
          "title": "Stroke Risk Factors, Genetics, and Prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the blood pressure\u2013lowering efficacy and general safety (death, vascular complications, renal artery stenosis, hypertensive crisis, renal function) of renal denervation in hypertensive patients. It does not involve thrombolysis, hemorrhagic conversion, or any analysis of intracranial bleeding risk relative to blood pressure levels. Therefore, it neither supports nor contradicts the proposed mechanism about elevated BP increasing hemorrhagic conversion risk after thrombolysis.",
          "key_findings": "Renal denervation reduced 24-hour systolic BP by 4.4 mmHg and office systolic BP by 6.6 mmHg versus sham, with parallel reductions in diastolic BP. Safety outcomes (all-cause death, vascular complications, renal artery stenosis, hypertensive crisis, renal function changes) were similar between RDN and sham. No data were reported on thrombolysis or hemorrhagic conversion.",
          "pmid": "39355923",
          "title": "Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses blood pressure management around ischemic stroke, including before and after intravenous thrombolysis, but it does not present data or explicit statements about the relationship between elevated blood pressure and risk of hemorrhagic transformation after thrombolysis. It focuses on overall functional outcome, mortality, and uncertainties in BP targets, not specifically on hemorrhagic conversion risk.",
          "key_findings": "High BP after ischemic stroke is described as common and associated with poor functional outcome and increased mortality. Large trials of BP lowering have not changed overall outcomes. The review notes that different subgroups (e.g., patients before or after thrombolysis) may need their BP lowered, left alone, or elevated, but provides no specific evidence or claims regarding elevated BP increasing hemorrhagic conversion risk post-thrombolysis.",
          "pmid": "35291822",
          "title": "Blood Pressure Management for Ischemic Stroke in the First 24 Hours.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension, BP variability, and cerebrovascular pathophysiology in general, but does not address thrombolysis, post-thrombolytic hemorrhagic transformation, or how elevated BP specifically affects hemorrhagic conversion risk after thrombolytic therapy.",
          "key_findings": "Hypertension and BP variability are linked to increased risks of ischemic and hemorrhagic stroke; arterial stiffness and increased pulsatility contribute to cerebrovascular injury; mechanisms such as cerebral small vessel disease, pulsatility, and cerebrovascular reactivity are described. No data or statements relate BP levels to hemorrhagic conversion risk following thrombolysis.",
          "pmid": "35255709",
          "title": "New Insights Into Cerebrovascular Pathophysiology and Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses migraine as a risk factor for stroke and mentions hypertension as a co-risk factor, but it does not address blood pressure levels after thrombolysis or their relationship to hemorrhagic conversion risk. No data or statements concern post-thrombolysis physiology or hemorrhagic transformation mechanisms.",
          "key_findings": "Migraine, particularly with aura, is described as an independent risk factor for stroke, especially when combined with other factors such as smoking or hypertension. The paper reviews shared pathophysiology and risk factors between migraine and stroke and notes that migraine is linked to worse ischemic stroke outcomes, but it does not mention thrombolytic therapy, blood pressure management post-thrombolysis, or hemorrhagic conversion.",
          "pmid": "39979846",
          "title": "Migraine and stroke: correlation, coexistence, dependence - a modern perspective.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses intracerebral hemorrhage care, including time-based blood pressure control and anticoagulation reversal, but does not address thrombolysis, hemorrhagic conversion after thrombolysis, or how elevated blood pressure specifically affects hemorrhagic conversion risk post-thrombolysis. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The consensus statement advocates ultra-early bundled care for intracerebral hemorrhage, emphasizing early blood pressure control and rapid reversal of anticoagulation to limit hematoma expansion and improve outcomes, but provides no data or discussion on post-thrombolysis hemorrhagic conversion risk or its relationship to elevated blood pressure.",
          "pmid": "38099439",
          "title": "Code ICH: A Call to Action.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses how endothelial cell senescence (promoted by factors including hypertension) disrupts the blood-brain barrier and may increase the risk of hemorrhagic transformation in ischemic stroke. However, it does not address blood pressure levels at the time of thrombolysis, nor does it evaluate whether elevated BP specifically increases hemorrhagic conversion risk post-thrombolysis. The mechanism in the abstract is framed in terms of cellular senescence and BBB disruption, not acute BP-related risk during thrombolytic therapy.",
          "key_findings": "Senescent endothelial cells accumulate with age and stressors such as hypertension; they alter tight junctions, increase BBB permeability, impair angiogenesis and vascular remodeling, and may thereby increase risk of hemorrhagic transformation and worsen stroke outcomes. The text does not mention thrombolytic treatment or the effect of elevated BP on post-thrombolysis hemorrhagic conversion risk.",
          "pmid": "39541552",
          "title": "Endothelial Cell Senescence Effect on the Blood-Brain Barrier in Stroke and Cognitive Impairment.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how elevated blood pressure affects risk of hemorrhagic conversion after thrombolysis. This trial examines primary prevention of first stroke (ischemic and hemorrhagic) with enalapril plus folic acid vs enalapril alone in hypertensive adults without prior stroke or thrombolytic treatment. It reports overall hemorrhagic stroke incidence but does not involve thrombolysis, hemorrhagic transformation of ischemic stroke, or BP levels immediately post-thrombolysis, so it neither supports nor contradicts the specific mechanistic claim.",
          "key_findings": "In hypertensive adults without prior stroke or MI, enalapril plus folic acid vs enalapril alone reduced first stroke (HR 0.79) and first ischemic stroke (HR 0.76), with no significant difference in hemorrhagic stroke risk (HR 0.93, 95% CI 0.65\u20131.34). No thrombolytic therapy, post-thrombolysis period, or hemorrhagic conversion of ischemic stroke was studied.",
          "pmid": "25771069",
          "title": "Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses migraine, ischemic and hemorrhagic stroke, and vascular risk factors such as hypertension in general terms, but it does not involve thrombolytic therapy, post-thrombolysis outcomes, or hemorrhagic conversion risk as a function of blood pressure. Therefore, it neither supports nor contradicts the specific mechanism that elevated BP increases hemorrhagic conversion risk after thrombolysis.",
          "key_findings": "The abstract notes an association between migraine (especially with aura) and ischemic and hemorrhagic stroke, mentions multiple potential contributing factors (vascular, inflammatory, endothelial, PFO, gender, OCP use, smoking), and states that vascular risk factors such as hypertension should be identified and modified in migraine patients. It does not mention thrombolysis or hemorrhagic transformation after thrombolytic therapy.",
          "pmid": "28989805",
          "title": "Migraine and stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates timing of antihypertensive medication, effects on ambulatory BP patterns, and overall cardiovascular and stroke outcomes, but it does not address thrombolysis, post-thrombolytic hemorrhagic conversion, or how elevated BP specifically influences hemorrhagic transformation risk after thrombolytic therapy.",
          "key_findings": "Bedtime ingestion of at least one BP-lowering drug, compared with all drugs upon awakening, resulted in lower sleep-time BP, greater sleep-time BP decline, reduced prevalence of non-dipping, higher prevalence of controlled ambulatory BP, and significantly reduced total and major cardiovascular events (including ischemic and hemorrhagic stroke). No data are presented on thrombolytic treatment or hemorrhagic conversion post-thrombolysis.",
          "pmid": "20854139",
          "title": "Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses genetics and general risk factors for intracerebral hemorrhage, including hypertension, but does not address blood pressure levels around thrombolysis, hemorrhagic conversion after thrombolytic therapy, or any BP\u2013related modulation of post-thrombolysis hemorrhage risk.",
          "key_findings": "ICH has genetic and polygenic risk factors such as hypertension, neurovascular inflammation, lipid metabolism and coagulation disorders, and small vessel disease; the paper reviews gene-related ICH types and mechanisms, without mentioning thrombolysis or hemorrhagic conversion risk associated with elevated blood pressure.",
          "pmid": "35886033",
          "title": "Intracerebral Hemorrhage Genetics.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses lacunar stroke, cerebral microangiopathy, arterial hypertension, and their roles in hemorrhagic and ischemic stroke risk, but it does not mention thrombolysis, post-thrombolytic hemorrhagic transformation, or the influence of elevated blood pressure on hemorrhagic conversion after thrombolytic therapy. Therefore it neither supports nor contradicts the specific mechanism about elevated BP increasing hemorrhagic conversion risk post-thrombolysis.",
          "key_findings": "Lacunar stroke is commonly associated with cerebral microangiopathy due to arterial hypertension and tandem atherosclerosis. Asymptomatic small deep infarcts and diffuse white matter pathology contribute to cognitive impairment and are predictors of severe hemorrhagic and ischemic stroke in patients with hypertension and atherosclerosis. No data are provided on thrombolytic treatment or hemorrhagic conversion after thrombolysis.",
          "pmid": "31825358",
          "title": "[Lacunar stroke].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses impaired cerebral autoregulation as a predictor of hemorrhagic transformation and cerebral edema in large territorial strokes, but it does not mention blood pressure levels, thrombolytic therapy, or hemorrhagic conversion specifically post-thrombolysis. Therefore, it neither supports nor contradicts the proposed mechanism that elevated blood pressure increases hemorrhagic conversion risk after thrombolysis.",
          "key_findings": "In large territorial strokes, impaired cerebral autoregulation is predictive of secondary complications such as hemorrhagic transformation and cerebral edema and is linked to worse functional outcome. No data are presented on systemic blood pressure levels, their elevation, or their interaction with thrombolytic therapy.",
          "pmid": "29785667",
          "title": "Cerebral Autoregulation in Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses spontaneous intracerebral hemorrhage risk factors, the importance of blood pressure management, and ongoing trials of intraventricular thrombolysis, but it does not examine hemorrhagic conversion risk after systemic thrombolysis (e.g., IV tPA for ischemic stroke) or directly relate elevated blood pressure to hemorrhagic transformation post-thrombolysis.",
          "key_findings": "Hypertension is listed as a risk factor for spontaneous intracerebral hemorrhage, and acute blood pressure control is under investigation to prevent hemorrhage expansion. Intraventricular thrombolysis with tPA is mentioned as part of an ICH treatment trial (CLEAR III), but without data or statements about elevated blood pressure influencing hemorrhagic conversion risk after thrombolysis.",
          "pmid": "21207348",
          "title": "Spontaneous intracerebral hemorrhage.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses TRPC channels in stroke, including their role in the initiation of stroke by affecting blood pressure, but it does not address post-thrombolysis outcomes or hemorrhagic conversion risk. There is no mention of thrombolytic therapy, intracerebral hemorrhage after thrombolysis, or how elevated blood pressure specifically alters hemorrhagic transformation risk, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "TRPC channels are implicated in neuronal death/survival in ischemic stroke, vasospasm in hemorrhagic stroke, thrombin-induced astrocyte changes, and the initiation of stroke via effects on blood pressure and atherogenesis; they are considered potential therapeutic targets due to their widespread distribution and diverse functions.",
          "pmid": "28508313",
          "title": "TRPC Channels and Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses chronic blood pressure targets for secondary stroke prevention and notes that intensive BP lowering reduces intracranial hemorrhage risk overall, but it does not address patients receiving thrombolysis, nor hemorrhagic conversion of an acute ischemic stroke after thrombolytic therapy. Thus it neither supports nor contradicts the specific mechanism that elevated BP increases hemorrhagic conversion risk post-thrombolysis.",
          "key_findings": "Hypertension is a major risk factor for stroke; lowering blood pressure reduces recurrent stroke by 25\u201330%. Intensive BP lowering to <130/80 mmHg further reduces recurrent stroke and intracranial hemorrhage compared to <140/90 mmHg. Guidelines recommend a target <130/80 mmHg, individualized based on risk of recurrent ischemic vs hemorrhagic stroke, with more aggressive lowering for those at high risk of intracranial hemorrhage.",
          "pmid": "35437312",
          "title": "Blood pressure management for secondary stroke prevention.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses elevated blood pressure as a risk factor for developing ischemic and hemorrhagic stroke in children, but it does not address thrombolysis, post-thrombolytic outcomes, or hemorrhagic conversion after thrombolytic therapy. Therefore it neither supports nor contradicts the specific mechanism that elevated BP increases hemorrhagic conversion risk post-thrombolysis.",
          "key_findings": "The review suggests that elevated blood pressure may be a significant risk factor for childhood ischemic and hemorrhagic stroke and recommends careful BP assessment in children with acute stroke, but provides no data on thrombolytic treatment or hemorrhagic transformation after thrombolysis.",
          "pmid": "28019129",
          "title": "Stroke and Hypertension in Children and Adolescents.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses dipyridamole\u2019s effects on cAMP/cGMP, nitric oxide signaling, vascular tone, platelet function, and infarct size, but it does not mention thrombolysis, hemorrhagic conversion, or how elevated blood pressure modifies hemorrhagic risk after thrombolytic therapy. The reference to eNOS-deficient mice having elevated blood pressure and larger infarcts concerns ischemic injury size, not hemorrhagic transformation post-thrombolysis.",
          "key_findings": "1) Dipyridamole increases cAMP and cGMP and inhibits platelet aggregation.\n2) It may potentiate endothelium-derived NO effects on vascular tone, blood flow, and perfusion.\n3) eNOS-deficient mice show elevated systemic blood pressure and larger myocardial and cerebral infarcts after ischemic injury.\n4) No data are presented on thrombolytic therapy or hemorrhagic conversion risk in relation to blood pressure.",
          "pmid": "18174451",
          "title": "Translational therapeutics of dipyridamole.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses ferroptosis in stroke pathogenesis in general and does not mention blood pressure levels, thrombolytic therapy, or hemorrhagic transformation after thrombolysis. Therefore, it provides no direct evidence for or against the proposed mechanism that elevated BP increases hemorrhagic conversion risk post-thrombolysis.",
          "key_findings": "The abstract describes ferroptosis as an iron-dependent form of cell death implicated in stroke, notes that stroke can be induced by hypertension among other factors, and explains that stroke leads to iron overload and lipid metabolism disorders triggering ferroptosis. It also notes that modulation of ferroptosis can alter stroke outcomes in animal models. No data are presented on blood pressure effects on hemorrhagic conversion after thrombolysis.",
          "pmid": "35102454",
          "title": "Role of Ferroptosis in Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The mechanism concerns how elevated blood pressure affects risk of hemorrhagic conversion after thrombolysis for ischemic stroke. This abstract analyzes blood pressure lowering strategies in patients with primary hemorrhagic stroke, not hemorrhagic transformation post-thrombolysis. It does not involve thrombolytic therapy or hemorrhagic conversion risk, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In patients with acute hemorrhagic stroke, intensive BP lowering (SBP <140 mmHg) versus guideline-level lowering (SBP <180 mmHg) led to reduced early hematoma growth but no significant difference in death or major disability or functional outcome overall. These data pertain to primary intracerebral hemorrhage management rather than hemorrhagic conversion after thrombolysis.",
          "pmid": "36884070",
          "title": "Early blood pressure management in hemorrhagic stroke: a meta-analysis.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "dbprand",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "BP levels can influence the systemic distribution and metabolization rate of alteplase, altering treatment effectiveness.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND (\"diastolic blood pressure\" OR \"blood pressure\" OR \"hypertension\") AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"metabolization\" OR \"effectiveness\" OR \"distribution\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses blood pressure analysis in intensive care for traumatic brain injury management but does not mention alteplase, its pharmacokinetics, or how blood pressure affects systemic distribution or metabolization of alteplase. Thus it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "The abstract notes that automated analysis of blood pressure and intracranial pressure can help individualize management of traumatic brain injury in intensive care, but provides no data on thrombolytic therapy, alteplase use, or blood pressure effects on drug distribution or metabolism.",
          "pmid": "36183712",
          "title": "Traumatic brain injury: progress and challenges in prevention, clinical care, and research.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on associations between short sleep duration and various health outcomes (including hypertension and stroke risk) but does not mention alteplase, thrombolytic therapy, pharmacokinetics, or how blood pressure alters the distribution or metabolism of alteplase. Thus it neither supports nor contradicts the specific pharmacological mechanism proposed.",
          "key_findings": "Short sleep duration is associated with increased risk of mortality (RR 1.12) and several conditions such as diabetes mellitus (RR 1.37), hypertension (RR 1.17), cardiovascular disease (RR 1.16), coronary heart disease (RR 1.26), and obesity (RR 1.38). A linear association between mortality and sleep duration <6 hours is reported. No data are presented on alteplase, its pharmacokinetics, or treatment effectiveness modulation by blood pressure.",
          "pmid": "27743803",
          "title": "Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses hypertension management, antihypertensive drug combinations, and general benefits of blood pressure reduction, but does not mention alteplase, thrombolytic therapy, or any pharmacokinetic/pharmacodynamic interaction between blood pressure levels and alteplase distribution or metabolism.",
          "key_findings": "Highlights hypertension as a major risk factor and summarizes trial results on: risks of combining ACE inhibitors and ARBs, benefits of fixed-dose calcium channel blocker plus ACE inhibitor, effectiveness of blood pressure reduction in patients older than 80 years, and introduction of oral renin inhibitors. No data on alteplase or on how blood pressure alters its systemic distribution or metabolization.",
          "pmid": "19701732",
          "title": "[Hypertension 2007-2008].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how blood pressure limits dose escalation of sacubitril/valsartan and relates maintenance dose to drug concentrations, but it does not involve alteplase, nor does it examine how blood pressure affects the systemic distribution or metabolism of alteplase specifically. Therefore, it is mechanistically unrelated to the proposed alteplase-focused claim.",
          "key_findings": "In pediatric heart failure patients treated with sacubitril/valsartan, dosing was titrated based on blood pressure to avoid hypotension (with a threshold around 70/50 mmHg). The active metabolite sacubitrilat reached its highest concentration at approximately 1.6 mg/kg, and maintenance dose correlated positively with both time and valsartan/sacubitril concentrations. No data on alteplase, its pharmacokinetics, or its relationship with blood pressure were reported.",
          "pmid": "39510399",
          "title": "Transforming pediatric heart failure: Efficacy of low-dose sacubitril/valsartan.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the efficacy and safety of various antihypertensive drugs in children and their effects on blood pressure levels, but it does not involve alteplase, thrombolytic therapy, or how blood pressure\u2013dependent pharmacokinetics or systemic distribution of alteplase might alter its effectiveness. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review shows that several antihypertensive agents (e.g., candesartan, telmisartan, metoprolol, bisoprolol/hydrochlorothiazide) modestly reduce systolic and/or diastolic blood pressure in children, with largely minor adverse events and no data on end organ outcomes. There is no discussion of alteplase, thrombolysis, stroke treatment pharmacokinetics, or blood-pressure-driven changes in drug distribution or metabolism.",
          "pmid": "25236305",
          "title": "Pharmacological interventions for hypertension in children.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how calcium supplementation affects blood pressure in normotensive individuals and its potential role in preventing hypertension. It does not involve alteplase, thrombolytic therapy, or any pharmacokinetics/pharmacodynamics related to how blood pressure might alter alteplase distribution or metabolism. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Calcium supplementation (various doses) produces small but statistically significant reductions in systolic and diastolic blood pressure in normotensive individuals, with somewhat larger effects in younger adults and in men. No data are presented on alteplase, drug distribution, metabolism, or treatment effectiveness.",
          "pmid": "35014026",
          "title": "Calcium supplementation for prevention of primary hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates comparative cardiovascular outcomes of antihypertensive drug classes and the association between blood pressure reduction and cardiovascular risk, but it does not involve alteplase use, its pharmacokinetics, or how blood pressure levels influence alteplase distribution or metabolism. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Different classes of antihypertensive medications (ACE inhibitors, dihydropyridine calcium channel blockers, and thiazide diuretics) showed similar effectiveness in reducing cardiovascular events compared with placebo; ACE inhibitors were most effective for myocardial infarction reduction and diuretics for revascularization reduction. A 10-mm Hg systolic and 5-mm Hg diastolic BP reduction was associated with lower cardiovascular death, stroke, and overall events. No data on alteplase or its pharmacological behavior are presented.",
          "pmid": "32083689",
          "title": "Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses clevidipine\u2019s pharmacokinetics (rapid metabolism by esterases, high clearance, low distribution) and its effectiveness for rapid blood pressure control, but it does not examine how blood pressure levels influence the systemic distribution or metabolism of another drug (alteplase), nor does it link BP modulation to altered alteplase treatment effectiveness.",
          "key_findings": "Clevidipine is an ultra-short-acting L-type calcium channel blocker with high clearance, low distribution volume, and rapid hydrolysis by nonspecific blood and tissue esterases; it effectively and rapidly lowers blood pressure in various acute settings (cardiac surgery, acute neurological injury, severe hypertension) and has adverse reactions similar to other antihypertensives.",
          "pmid": "34472038",
          "title": "The Current Role of Clevidipine in the Management of Hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how different antihypertensive drug classes affect blood pressure variability and stroke risk. It does not involve alteplase, thrombolytic therapy, or how blood pressure levels influence the systemic distribution or metabolization rate of alteplase, nor does it address treatment effectiveness of alteplase. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Calcium-channel blockers and non-loop diuretics reduced interindividual variation in systolic blood pressure, whereas ACE inhibitors, angiotensin-receptor blockers, and beta blockers increased it. Variation in systolic blood pressure and changes in mean systolic blood pressure both contributed to differences in stroke risk between drug classes, independent of mean blood pressure effects. No data are presented on alteplase pharmacokinetics, distribution, metabolism, or its interaction with blood pressure levels.",
          "pmid": "20226989",
          "title": "Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how various antihypertensive drugs change blood pressure levels in children but does not involve alteplase, thrombolytic therapy, or how blood pressure influences the distribution or metabolism of alteplase. It reports BP-lowering effects and safety of antihypertensives only, without pharmacokinetic or pharmacodynamic data relevant to alteplase.",
          "key_findings": "The review shows that certain antihypertensives (e.g., candesartan, telmisartan, metoprolol) modestly lower systolic and/or diastolic blood pressure in children and are generally safe short-term. No trials assess effects on drug distribution, metabolism, or on alteplase treatment effectiveness.",
          "pmid": "24488616",
          "title": "Pharmacological interventions for hypertension in children.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how calcium supplementation changes blood pressure in normotensive individuals and its role in preventing hypertension. It does not involve alteplase, thrombolytic therapy, drug pharmacokinetics, or how blood pressure might alter systemic distribution or metabolism of alteplase. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Calcium supplementation (typically 1000\u20131500 mg/day) produces small but statistically significant reductions in systolic and diastolic blood pressure in normotensive people, with somewhat larger effects in younger individuals and men. No adverse events were reported. The review suggests a potential role for calcium in preventing primary hypertension but does not address drug distribution or metabolism, nor any interaction with alteplase.",
          "pmid": "34693985",
          "title": "Calcium supplementation for prevention of primary hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how pregnancy-related physiological changes (e.g., increased plasma volume, decreased protein binding, altered clearance) affect the pharmacokinetics of antihypertensive drugs in general. It does not examine alteplase, thrombolytics, or how blood pressure levels per se influence systemic distribution or metabolization of alteplase, nor does it link BP level changes directly to alterations in pharmacokinetics of any drug. Thus it is only broadly related to pharmacokinetic modulation by physiologic state, not to the specific mechanism proposed.",
          "key_findings": "Pregnancy can increase plasma volume and decrease protein binding, altering drug volume of distribution; clearance can increase or decrease depending on elimination pathways; these changes can affect elimination half-life and necessitate dose or interval adjustments for antihypertensive medications. Data in pregnant women are limited and better pharmacokinetic/pharmacodynamic studies are needed.",
          "pmid": "19385709",
          "title": "Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thromboxane/prostaglandin receptor antagonism (ifetroban), its pharmacology, tissue distribution, and effects on hypertension, stroke, and platelets, but it does not mention alteplase, fibrinolytic therapy, or how blood pressure levels influence the distribution or metabolism of alteplase. Therefore it neither supports nor contradicts the proposed mechanism about BP-dependent alteplase pharmacokinetics.",
          "key_findings": "Ifetroban sodium is described as an effective thromboxane A2/prostaglandin H2 receptor antagonist with studied chemistry, pharmacokinetics, pharmacodynamics, tissue distribution, and effects in hypertension, stroke, thrombosis, and platelet function; hypertension is associated with increased thromboxane A2 and platelet hyperaggregability. No data are presented regarding alteplase, its systemic distribution, metabolism, or modulation by blood pressure.",
          "pmid": "11484065",
          "title": "Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses the biochemistry, pharmacokinetics, and clinical uses of glycerol, including its effects on serum osmolality, body water, and tolerance to heat/exercise. It does not mention alteplase, thrombolytic therapy, blood pressure effects on drug distribution or metabolism, or any interaction between blood pressure levels and pharmacokinetics of alteplase. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Glycerol is a 3\u2011carbon alcohol involved in triacylglycerol structure and glycolysis; serum levels rise with lipolysis and with ingestion/infusion above 1 g/kg. High doses increase serum osmolality and have been used clinically for cerebral edema, intraocular and intracranial hypertension, syncope, and to enhance rehydration. Glycerol hyperhydration can increase total body water and improve thermoregulation and endurance in heat. No data on alteplase, blood pressure effects on drug distribution, or metabolization rates.",
          "pmid": "9802172",
          "title": "Glycerol. Biochemistry, pharmacokinetics and clinical and practical applications.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how losartan/hydrochlorothiazide lowers blood pressure and reduces stroke risk, but it does not mention alteplase, its pharmacokinetics, systemic distribution, or metabolization, nor any interaction between blood pressure levels and alteplase treatment effectiveness.",
          "key_findings": "Losartan/HCTZ effectively lowers blood pressure and reduces stroke risk in hypertensive patients with left ventricular hypertrophy; losartan-based therapy showed lower cardiovascular morbidity/mortality and stroke risk compared with atenolol-based therapy. No data are presented on alteplase or on how blood pressure affects alteplase distribution or metabolism.",
          "pmid": "19537840",
          "title": "Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses nifedipine\u2019s role and formulations in treating coronary heart disease and hypertension, focusing on safety, effectiveness, and pharmacokinetic advantages of controlled-release systems. It does not mention alteplase, thrombolytic therapy, or how blood pressure levels influence systemic distribution or metabolism of alteplase, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Short-acting nifedipine had suboptimal pharmacokinetics and possible dangerous effects in secondary prevention; newer controlled-release (GITS) formulations show effectiveness and safety in large RCTs and are favored in guidelines. No data on alteplase or BP-dependent changes in alteplase distribution/metabolism.",
          "pmid": "17605643",
          "title": "Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses blood pressure control using antihypertensive combinations (lercanidipine and enalapril) and mechanisms of hypertension, but it does not mention alteplase, its pharmacokinetics, or how blood pressure levels might affect alteplase distribution or metabolism. Therefore it neither supports nor contradicts the proposed alteplase-specific pharmacological mechanism.",
          "key_findings": "The abstract reports that combination therapy with lercanidipine and enalapril effectively reduces blood pressure and has a favorable safety profile; it describes pathophysiologic mechanisms of hypertension and rationale for combination therapy, but provides no data on alteplase, thrombolytic treatment, or blood pressure effects on drug distribution/metabolism.",
          "pmid": "27895487",
          "title": "Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses sex-based differences in pharmacokinetics, pharmacodynamics, and drug-metabolizing enzymes broadly, but it does not address blood pressure effects on systemic distribution or metabolism of alteplase (or thrombolytics in relation to BP). The mention of hemorrhagic stroke after thrombolytic therapy is not linked to BP-mediated changes in alteplase distribution or clearance.",
          "key_findings": "Women have higher mortality after MI and higher rates of hemorrhagic stroke after thrombolytic therapy; sex differences exist in drug-induced QT prolongation, analgesic response, and the activity of various drug-metabolizing enzymes (e.g., CYP3A4, TPMT, P-glycoprotein). None of these findings relate BP levels to the pharmacokinetics or pharmacodynamics of alteplase.",
          "pmid": "12396893",
          "title": "Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses modern contraceptive methods, their risks, benefits, and efficacy, but does not mention blood pressure, alteplase, systemic drug distribution, or metabolization rates. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Improvements in oral contraceptives, Norplant, and IUDs; reduced major risks of oral contraceptives; recognition of noncontraceptive health benefits; Norplant offers long-term contraception with modest risks; IUD is safe and effective when users are carefully selected, with reduced risk of pelvic inflammatory disease by avoiding use in high-risk individuals.",
          "pmid": "2128711",
          "title": "Modern trends in contraception.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses Uncaria species, their antihypertensive and other pharmacological properties, and the pharmacokinetics of their indole alkaloids, including CYP-mediated metabolism. It does not mention alteplase, thrombolytic therapy, or how blood pressure levels might alter the systemic distribution or metabolization rate of alteplase, nor does it address interactions between blood pressure and drug pharmacokinetics in a way that can be extrapolated specifically to alteplase.",
          "key_findings": "Uncaria species are used for hypertension and other conditions; over 200 compounds, especially indole alkaloids, have been identified. Indole alkaloids are absorbed, metabolized, and excreted early, and CYP isozyme inhibition can regulate their hydroxylation at C-10 and C-11. No data are presented on alteplase, its distribution, metabolism, or modulation of its effects by blood pressure levels.",
          "pmid": "26091967",
          "title": "Medicinal uses, phytochemistry and pharmacology of the genus Uncaria.",
          "analysis_method": "llm"
        }
      ]
    }
  ]
}